A dimer compound having a benzo[b]selenophene structure and its use

By synthesizing a dimer compound with a benzo[b]selenophene structure, the problem of insufficient agonistic ability of existing STING agonists was solved, achieving efficient activation of STING protein and enhanced anti-tumor activity, which is suitable for tumor immunotherapy.

CN116332903BActive Publication Date: 2024-11-12CHINA PHARM UNIV
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202310321063.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-03-29
Publication Date
2024-11-12
Estimated Expiration
2043-03-29

AI Technical Summary

Technical Problem

Existing STING agonists suffer from insufficient agonistic capacity and poor anti-tumor effects in tumor immunotherapy, necessitating the development of novel and highly effective STING agonists to broaden market demand.

Method used

A dimer compound with a benzo[b]selenophene structure was designed and synthesized. By optimizing the molecular structure to improve the affinity and agonistic ability of STING protein, the cGAS-STING pathway was activated, thereby enhancing antitumor activity.

Benefits of technology

This compound has a good affinity for STING protein, can effectively activate the cGAS-STING pathway, enhance the activity of THP1 cells in secreting IFNβ, and has excellent anti-tumor effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116332903B_ABST
    Figure CN116332903B_ABST
Patent Text Reader

Abstract

The present invention discloses a dimeric compound having a benzo[b]selenophene structure having a structure shown in the general formula (I) or a pharmaceutically acceptable salt, isomer, metabolite, solvate or prodrug thereof, and a pharmaceutical composition thereof. Such compounds have good agonist activity on the cGAS-STING pathway and can provide a basis for the preparation of drugs that activate the cGAS-STING pathway. At the same time, the compounds of the present invention have good activity in inducing THP1 cells to secrete IFNβ, and can be used to prepare drugs for preventing and / or treating STING-related diseases, or used in combination with immune checkpoint inhibitors to prepare anti-tumor drugs. #imgabs0#
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of chemical medicine, and specifically relates to a dimer compound with a benzo[b]selenophene structure and a use thereof. Background Art

[0002] The cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway is an important component of the body's innate immune system, playing an important role in combating the invasion of exogenous pathogens (bacteria, viruses, etc.) and eliminating endogenous damage (dead cells, tumor cells, etc.). Abnormal double-stranded DNA (dsDNA) signals in the cytoplasm can be recognized by cGAS, thereby triggering a series of subsequent biological cascade reactions. cGAS is activated after binding to dsDNA, and can catalyze the cyclization of GMP and AMP to generate cyclic GMP-AMP (cGAMP). As a second messenger, cGAMP recognizes and binds to the endoplasmic reticulum membrane protein STING. STING then undergoes a conformational change and further moves to the Golgi apparatus. On the Golgi apparatus, the STING protein oligomerizes and recruits TBK1, which further participates in the phosphorylation of transcription factors IRF3 and NF-κB. The phosphorylated transcription factors then enter the cell nucleus and induce the transcription and expression of downstream type I interferon (IFN), thereby enhancing the body's innate immunity and related acquired immunity.

[0003] Studies have shown that activation of the cGAS-STING pathway can promote the expression and secretion of type I IFN and other cytokines (such as IL6, TNFα, CXCL10, etc.), which in turn promote the maturation of antigen-presenting cells, such as dendritic cells and macrophages. Antigen-presenting cells cross-present antigens and subsequently recruit and activate CD8 + T cells, thereby killing tumor cells or clearing pathogen infection. Therefore, activating the cGAS-STING pathway can simultaneously activate the innate and adaptive immune systems and is considered an effective means of treating tumors and infectious diseases.

[0004] As a key protein in this pathway, STING has received increasing attention from the pharmaceutical industry in recent years. So far, many companies at home and abroad have developed STING agonists, among which Merck's MK-1454 is currently in Phase 2 clinical trials, combined with the anti-PD-1 monoclonal antibody Keytruda for the treatment of metastatic or recurrent head and neck cancer, and there are still a number of products undergoing Phase 1 or Phase 1 / 2 clinical trials. Most of these STING agonists are cyclic dinucleotide derivatives that mimic the natural ligand cGAMP. In addition, some non-cyclic dinucleotide STING agonists have also been disclosed, including aminobenzimidazole compounds (WO2017175147), imidazole pyridazine compounds (WO2019165032), benzothiophene compounds (WO2019165032) and benzoselenophene compounds (CN113429387A), etc., which activate STING protein and are used to treat a variety of diseases, including cancer.

[0005] Therefore, STING agonists are of great significance in disease treatment, especially in the application of tumor immunotherapy, and there is an urgent need to develop new and highly efficient STING agonists to expand market demand. Summary of the invention

[0006] Purpose of the invention: The purpose of the present invention is to provide a dimeric compound having a benzo[b]selenophene structure as in general formula I and its use. These compounds have a strong affinity for the STING protein, have good stimulatory ability for the cGAS-STING pathway, and have excellent effects on anti-tumor activity.

[0007] The present invention provides a compound of general formula I, or a pharmaceutically acceptable salt, isomer, metabolite, solvate or prodrug thereof:

[0008]

[0009] in,

[0010] L 1 and L 3 are the same or different and are each independently selected from C(R 5 )2. NR 5 , O or S;

[0011] L 2 Selected from C1-C6 alkylene, R 6 Substituted C1-C6 alkylene, C1-C6 alkylene-L 4 -C1-C6 alkylene, C2-C6 alkenylene, C2-C6 haloalkenylene, C2-C6 alkynylene, C2-C6 haloalkynylene, C3-C6 cycloalkyl or 3-6 membered heterocyclic group;

[0012] L 4 Selected from O, S, C(O), C(O)NR 5 、S(O)、S(O)2、S(O)2NR 5 , C3-C6 cycloalkyl or 3-6 membered heterocyclic group;

[0013] X 1 and X 4 Selected from C(O);

[0014] X 2 and X 5 Selected from (C(R 7 )2) p ;

[0015] X 3 and X 6 The same or different, and each independently selected from COOR 5 、C(O)N(R 5 )2、C(O)NR 5 OR 5 、C(O)ON(R 5 2. SO2R 5 、S(O)NR 5 or C(CF3)2OR 5 ;

[0016] A 1 Selected from Se, S, O or NH;

[0017] R 1 and R 2 are the same or different and are each independently selected from hydrogen, halogen, cyano, nitro, OR 5 , SR 5 、N(R 5 2. COOR 5 、C(O)N(R 5 )2, C1~C6 alkyl, C1~C6 haloalkyl, OR 5 Substituted C1-C6 alkyl, N(R 5 )2-substituted C1-C6 alkyl, C2-C6 alkenyl, C2-C6 haloalkenyl, C2-C6 alkynyl, C2-C6 haloalkynyl, C3-C6 cycloalkyl or 3-6 membered heterocyclic group;

[0018] R 3 and R 4 are the same or different and are each independently selected from hydrogen, halogen, cyano, OR 5 、N(R 5 )2, C1~C6 alkyl, C1~C6 haloalkyl or C3~C6 cycloalkyl;

[0019] R 5 is selected from hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, 3-6 membered heterocyclic group or C5-C 10 Aryl;

[0020] R 6 Selected from hydrogen, halogen, OR 5 、N(R 5 )2, C1-C6 alkyl, C1-C6 haloalkyl, C3-C6 cycloalkyl or 3-6 membered heterocyclic group;

[0021] R 7 Selected from hydrogen, halogen, cyano, OR 5 、N(R 5 )2, C1~C6 alkyl, C1~C6 haloalkyl, OR 5 Substituted C1~C6 alkyl or C3~C6 cycloalkyl;

[0022] Optionally, the two R on different carbon atoms 7 Together with the carbon atoms between them, they can form a C3-C6 cycloalkyl group or a 3-6 membered heterocyclic group;

[0023] Optionally, two R on the same carbon atom 7 Together with the carbon atom to which they are commonly attached, they may form a C3-C6 cycloalkyl group or a 3-6 membered heterocyclic group;

[0024] m and n are each independently selected from 0, 1, 2 and 3;

[0025] p is selected from 1, 2 and 3.

[0026] The compound of the general formula I of the present invention or its pharmaceutically acceptable salt, isomer, metabolite, solvate or prodrug, preferably a compound having the structure of formula (Ia), formula (Ib), formula (Ic) or formula (Id):

[0027]

[0028] Among them, L 1 , L 2 , L 3 , X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , A 1 , R 1 , R 2 , R 3 , R 4 As defined in Formula I.

[0029] In certain preferred embodiments,

[0030] L 1 and L 3 are the same or different and are each independently selected from CH2, NH or O;

[0031] L 2 Selected from C1-C6 alkylene, R 6 Substituted C1-C6 alkylene, C1-C4 alkylene-L 4 -C1-C4 alkylene, C2-C4 alkenylene, C2-C4 haloalkenylene, C2-C4 alkynylene, C2-C4 haloalkynylene, C3-C6 cycloalkyl or 3-6 membered heterocyclic group;

[0032] L 4 is selected from O, S, C(O), C3-C6 cycloalkyl or 3-6 membered heterocyclic group;

[0033] X 1 and X 4 Selected from C(O);

[0034] X 2 and X 5 Selected from (C(R 7 )2) p ;

[0035] X 3 and X 6 The same or different, and each independently selected from COOR 5 、C(O)N(R 5 )2、C(O)NR 5 OR 5 or C(O)ON(R 5 )2;

[0036] A 1 Selected from Se or S;

[0037] R 1 and R 2 are the same or different and are each independently selected from hydrogen, halogen, C1-C3 alkyl, C1-C3 haloalkyl, -O-C1-C3 alkyl, -O-C1-C3 haloalkyl or OH;

[0038] R 3 and R 4 are the same or different and are each independently selected from hydrogen, fluorine, and C1-C3 alkyl;

[0039] R 5 is selected from hydrogen, C1-C3 alkyl, C1-C3 haloalkyl, C3-C6 cycloalkyl, 3-6 membered heterocyclic group or C5-C 10 Aryl;

[0040] R 6 is selected from hydrogen, fluorine, OH, NH2, C1-C4 alkyl, C1-C4 haloalkyl, C3-C6 cycloalkyl or 3-6 membered heterocyclic group;

[0041] R 7 Selected from hydrogen, fluorine, -O-C1~C3 alkyl, C1~C4 alkyl, C1~C4 haloalkyl, -O-C1~C3 alkyl substituted C1~C4 alkyl or C3~C6 cycloalkyl;

[0042] Optionally, the two R on different carbon atoms 7 Together with the carbon atoms between them, they can form a C3-C6 cycloalkyl group or a 3-6 membered heterocyclic group;

[0043] Optionally, two R on the same carbon atom 7 Together with the carbon atom to which they are commonly attached, they may form a C3-C6 cycloalkyl group or a 3-6 membered heterocyclic group;

[0044] p is selected from 1, 2 and 3.

[0045] In certain further preferred embodiments,

[0046] L 2 Selected from C2-C5 alkylene, R 6 Substituted C2-C5 alkylene or C1-C4 alkylene-L 4 -C1~C4 alkylene;

[0047] L 4 Selected from O or C(O);

[0048] X 3 and X 6 are the same or different and are each independently selected from COOH, COOCH3, COOCH2CH3, C(O)NH2, C(O)NHOH, C(O)NHOCH3 or C(O)ONHCH(CH3)2;

[0049] R 1 and R 2 are the same or different and are each independently selected from hydrogen, fluorine, chlorine, CH3, CH2CH3, OCH3, OCH2CH3, OCH(CH3)2 or OCHF2;

[0050] R 3 and R 4 Selected from hydrogen;

[0051] R 6 is selected from hydrogen, fluorine, CH3, CH2CH3, OH or cyclopropyl;

[0052] R7 is selected from hydrogen, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, CH2OCH3 or cyclopropyl;

[0053] p=2.

[0054] In certain further preferred embodiments,

[0055] X 2 and X 5 Selected from CHR 7 CHR 7 ;

[0056] X 3 and X 6 Selected from COOH.

[0057] In certain further preferred embodiments,

[0058] X 2 and X 5 Selected from CH2C(R 7 )2;

[0059] X 3 and X 6 Selected from COOH.

[0060] The compounds of the general formula I of the present invention are preferably the following compounds:

[0061]

[0062]

[0063]

[0064]

[0065] The term "pharmaceutically acceptable salt" refers to a salt prepared from a compound of the general formula I of the present invention and a pharmaceutically acceptable non-toxic base, including an organic base or an inorganic base. Salts derived from pharmaceutically acceptable organic bases include salts of primary, secondary and tertiary amines, and substituted amines include naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as betaine, caffeine, choline, N-ethylpiperidine, N,N'-dibenzylethylenediamine, diethylamine, 2-dimethylaminoethanol, arginine, ethanolamine, ethylenediamine, N-ethylmorpholine, glucosamine, methylglucosamine, 2-diethylaminoethanol, glucosamine, histidine, aminoethanol, hydroxocobalamin, lysine, morpholine, piperazine, piperidine, quaternium, polyamine resins, triethylamine, trimethylamine, tripropylamine, isopropylamine, tromethamine, etc. Salts derived from pharmaceutically acceptable inorganic bases include aluminum salts, ammonium salts, calcium salts, lithium salts, magnesium salts, potassium salts, sodium salts, zinc salts, etc.

[0066] The term "isomers" refers to compounds that have the same chemical formula but different arrangements of the atoms.

[0067] The term "metabolite" refers to a pharmaceutically active product produced by the metabolism of a compound of the invention in vivo. Such products may be produced, for example, from oxidation, reduction, hydrolysis, amidation, deamidation, esterification, deesterification, glucuronidation, enzymatic cleavage, etc. of the administered compound. Thus, the present invention includes metabolites of the compounds of the invention, including compounds produced by a process of contacting a compound of the invention with a mammal for a period of time sufficient to produce a metabolic product thereof.

[0068] The term "solvate" refers to a complex in which the compound of the present invention is coordinated with solvent molecules to form a specific ratio.

[0069] The term "prodrug" includes a substance which may be biologically active or inactive, and which undergoes metabolism or chemical reactions in the human body after being taken by an appropriate method to be converted into a compound of Formula I, or a salt or solution composed of a compound of Formula I. The prodrug includes, but is not limited to, carboxylate, carbonate, phosphate, nitrate, sulfate, sulfone, sulfoxide, amino compound, carbamate, azo compound, phosphoramide, glucoside, ether, acetal and the like forms of the compound.

[0070] When the compound has the structure shown in general formula (I-1), the synthesis route is as follows:

[0071]

[0072] Among them, R 1 , R 2 , R 7 , L 2 , m and n are as defined above, R 8 is selected from CH3, CH2CH3 or C(CH3)3, R 9 is selected from CH3 or CH2CH3, and Y is selected from Cl, Br or I. The preparation method of compound 18 is the same as that of compound 15.

[0073] In some more specific embodiments, R1 and R2 are selected from hydrogen, fluorine, chlorine, CH3, CH2CH3, OCH3, OCH2CH3, OCH(CH3)2 or OCHF2; L2 is selected from C2-C5 alkylene, R 6 Substituted C2-C5 alkylene or C1-C4 alkylene-L 4 -C1~C4 alkylene; R6 is selected from hydrogen, fluorine, CH3, CH2CH3, OH or cyclopropyl, L4 is selected from O or C(O); R7 is selected from hydrogen, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, CH2OCH3 or cyclopropyl.

[0074] A specific preparation method of the compound of general formula (I-1) comprises the following steps:

[0075] (1) Compound 1 and Compound 2 (benzyl bromide) are subjected to substitution reaction to obtain benzyl-protected Compound 3, wherein the reaction reagent is selected from potassium carbonate, sodium carbonate, sodium hydroxide or sodium hydride, and the reaction solvent is selected from DMF or tetrahydrofuran;

[0076] (2) Compound 3 reacts with compound 4 (dimethyl diselenide) to obtain compound 5, the reaction reagent is selected from DTT, mercaptoethanol, DBU or potassium carbonate, and the reaction solvent is selected from DMF or tetrahydrofuran;

[0077] (3) Compound 5 and compound 6 (ethyl 2-bromoacetate) are subjected to substitution reaction to obtain compound 7, and the reaction solvent is DMF;

[0078] (4) Compound 7 is subjected to an intramolecular condensation reaction to obtain compound 8, wherein the reaction reagent is selected from potassium carbonate, sodium carbonate, cesium carbonate, sodium hydroxide or lithium hydroxide, and the reaction solvent is selected from DMF or acetonitrile;

[0079] (5) Compound 8 is hydrolyzed to obtain compound 9, the reaction reagent is selected from potassium carbonate, sodium hydroxide or strong lithium oxide, and the reaction solvent is selected from water, methanol and tetrahydrofuran;

[0080] (6) Compound 9 and compound 10 (malonic acid monoester potassium salt) are subjected to condensation reaction to obtain compound 11, the reaction reagent is selected from CDI and MgCl2, and the reaction solvent is selected from DMF or tetrahydrofuran;

[0081] (7) Compound 11 and compound 12 (haloester) are subjected to substitution reaction to obtain compound 13, the reaction reagent is selected from potassium carbonate, sodium methoxide, sodium ethoxide or sodium hydride, and the reaction solvent is selected from DMF or tetrahydrofuran;

[0082] (8) Compound 13 is hydrolyzed to obtain compound 14, the reaction reagent is selected from potassium carbonate, sodium hydroxide, lithium hydroxide or hydrochloric acid, and the reaction solvent is selected from acetic acid, water or tetrahydrofuran;

[0083] (9) Compound 14 is protected by ester to obtain compound 15, the reaction reagent is selected from thionyl chloride or oxalyl chloride, and the reaction solvent is selected from methanol, ethanol or dichloromethane;

[0084] (10) Compound 15 and compound 16 (dihaloalkane) are subjected to substitution reaction to obtain compound 17, wherein the reaction reagent is selected from potassium carbonate, sodium carbonate, cesium carbonate, sodium hydroxide, lithium hydroxide, potassium iodide or crown ether, and the reaction solvent is selected from DMF or tetrahydrofuran;

[0085] (11) Compound 17 and Compound 18 are dimerized to obtain Compound 19, wherein the reaction reagent is selected from potassium carbonate, sodium carbonate, cesium carbonate, sodium hydroxide, lithium hydroxide, potassium iodide or crown ether, and the reaction solvent is selected from DMF or tetrahydrofuran;

[0086] (12) Compound 19 is hydrolyzed to obtain a compound of formula (I-1), wherein the reaction reagent is selected from potassium carbonate, sodium hydroxide or lithium hydroxide, and the reaction solvent is selected from water, methanol and tetrahydrofuran.

[0087] When the compound has the structure shown in general formula (I-2), the synthesis route is as follows:

[0088]

[0089] Among them, R 1 , R 2 , L 2 , m and n are as defined above, R 9 is selected from CH3 or CH2CH3, Y is selected from Cl, Br or I, and q is selected from 1, 2, 3 or 4. The preparation method of compound 26 is the same as that of compound 24.

[0090] In some more specific embodiments, R1 and R2 are selected from hydrogen, fluorine, chlorine, CH3, CH2CH3, OCH3, OCH2CH3, OCH(CH3)2 or OCHF2; L2 is selected from C2-C5 alkylene, R 6 Substituted C2-C5 alkylene or C1-C4 alkylene-L 4 -C1~C4 alkylene; R6 is selected from hydrogen, fluorine, CH3, CH2CH3, OH or cyclopropyl; L4 is selected from O or C(O).

[0091] A specific preparation method of the compound of general formula (I-2) comprises the following steps:

[0092] (1) Compound 20 is obtained by decarboxylation reaction of compound 9, the reaction reagent is copper powder, and the reaction solvent is quinoline;

[0093] (2) Compound 20 and compound 21 (substituted succinic anhydride) are subjected to Friedel-Crafts acylation to obtain compound 22, wherein the reaction reagent is selected from aluminum trichloride, zinc chloride or titanium tetrachloride, and the reaction solvent is selected from dichloromethane or tetrahydrofuran;

[0094] (3) Compound 22 is debenzylated to obtain compound 23, the reactant is hydrogen, the reagent is selected from palladium / carbon or palladium hydroxide / carbon, and the reaction solvent is selected from tetrahydrofuran or methanol;

[0095] (4) Compound 23 is protected by ester to obtain compound 24, the reaction reagent is selected from thionyl chloride or oxalyl chloride, and the reaction solvent is selected from methanol, ethanol or dichloromethane;

[0096] (5) Compound 24 and compound 16 (dihaloalkane) are subjected to substitution reaction to obtain compound 25, wherein the reaction reagent is selected from potassium carbonate, sodium carbonate, cesium carbonate, sodium hydroxide, lithium hydroxide, potassium iodide or crown ether, and the reaction solvent is selected from DMF or tetrahydrofuran;

[0097] (6) Compound 25 and compound 26 are dimerized to obtain compound 27, the reaction reagent is selected from potassium carbonate, sodium carbonate, cesium carbonate, sodium hydroxide, lithium hydroxide, potassium iodide or crown ether, and the reaction solvent is selected from DMF or tetrahydrofuran.

[0098] (7) Compound 27 is subjected to ester hydrolysis reaction to obtain a compound of formula (I-2), wherein the reaction reagent is selected from potassium carbonate, sodium hydroxide or lithium hydroxide, and the reaction solvent is selected from water, methanol and tetrahydrofuran.

[0099] When the compound has the structure shown in general formula (I-3), the synthesis route is as follows:

[0100]

[0101] Among them, R 1 , R 2 , R 7 and L 2 As defined above, R 8 is selected from CH3, CH2CH3 or C(CH3)3, R 9 is selected from CH3 or CH2CH3, and Y is selected from Cl, Br or I.

[0102] In some more specific embodiments, R1 and R2 are selected from hydrogen, fluorine, chlorine, CH3, CH2CH3, OCH3, OCH2CH3, OCH(CH3)2 or OCHF2; L2 is selected from C2-C5 alkylene, R 6 Substituted C2-C5 alkylene or C1-C4 alkylene-L 4 -C1~C4 alkylene; R6 is selected from hydrogen, fluorine, CH3, CH2CH3, OH or cyclopropyl; L4 is selected from O or C(O).

[0103] A specific preparation method of the compound of general formula (I-3) comprises the following steps:

[0104] (1) Compound 3 and compound 28 (methyl thioglycolate) were reacted by a one-step substitution and cyclization reaction to obtain compound

[0105] Compound 29, the reaction reagent is selected from potassium carbonate, cuprous iodide and diethylamine, and the reaction solvent is DMF;

[0106] (2) Compound 29 is subjected to ester hydrolysis to obtain compound 30, wherein the reaction reagent is selected from potassium carbonate, sodium hydroxide or strong lithium oxide, and the reaction solvent is selected from water, methanol and tetrahydrofuran;

[0107] (3) Compound 30 and compound 10 (malonic acid monoester potassium salt) are subjected to condensation reaction to obtain compound 31, the reaction reagent is selected from CDI and MgCl2, and the reaction solvent is selected from DMF or tetrahydrofuran;

[0108] (4) Compound 31 and compound 12 (haloester) undergo substitution reaction to obtain compound 32, the reaction reagent is selected from potassium carbonate, sodium methoxide, sodium ethoxide or sodium hydride, and the reaction solvent is selected from DMF or tetrahydrofuran;

[0109] (5) Compound 32 is hydrolyzed to obtain compound 33, the reaction reagent can be potassium carbonate, sodium hydroxide, lithium hydroxide or hydrochloric acid, and the reaction solvent is selected from acetic acid, water or tetrahydrofuran;

[0110] (6) Compound 33 is protected by ester group to obtain compound 34, the reaction reagent is selected from thionyl chloride or oxalyl chloride, and the reaction solvent is selected from methanol, ethanol or dichloromethane;

[0111] (7) Compound 34 and compound 16 (dihaloalkane) are subjected to substitution reaction to obtain compound 35, wherein the reaction reagent is selected from potassium carbonate, sodium carbonate, cesium carbonate, sodium hydroxide, lithium hydroxide, potassium iodide or crown ether, and the reaction solvent is selected from DMF or tetrahydrofuran;

[0112] (8) Compound 35 is condensed with compound 18 to obtain compound 36, the reaction reagent is selected from potassium carbonate, sodium carbonate, cesium carbonate, sodium hydroxide, lithium hydroxide, potassium iodide or crown ether, and the reaction solvent is selected from DMF or tetrahydrofuran;

[0113] (9) Compound 36 is hydrolyzed to obtain a compound of formula (I-3), wherein the reaction reagent is selected from potassium carbonate, sodium hydroxide or lithium hydroxide, and the reaction solvent is selected from water, methanol and tetrahydrofuran.

[0114] The present invention also provides a pharmaceutical composition comprising one or more therapeutically effective amounts of the compound of formula I described in the present invention or a pharmaceutically acceptable salt, isomer, metabolite, solvate or prodrug thereof, and a pharmaceutically acceptable carrier or excipient.

[0115] In certain preferred embodiments, the pharmaceutical composition is in the form of tablets, capsules, pills, powders, granules, solutions, suspensions or injections, and the administration method is oral administration or injection.

[0116] Commonly used pharmaceutically acceptable carriers or excipients include stabilizers, diluents, surfactants, lubricants, antioxidants, binders, colorants, fillers, emulsifiers, and the like.

[0117] Sterile injectable compositions can be formulated using suitable dispersing agents or wetting agents and suspending agents according to techniques known in the art. Pharmaceutically acceptable carriers and solvents that can be used include water, mannitol, sodium chloride solution, and the like.

[0118] Topical compositions may be formulated as oils, lotions, creams, etc. Carriers for the compositions include vegetable or mineral oils, animal fats, and high molecular weight alcohols, etc. Pharmaceutically acceptable carriers are carriers in which the active ingredient is soluble.

[0119] The actual dosage level of the active ingredient in the pharmaceutical composition of the present invention can be varied to obtain an amount of the active ingredient that is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient. The dosage level selected depends on a variety of factors, including the activity of the specific compound of the present invention or its salt used, the route of administration, the time of administration, the excretion rate of the specific composition used, the duration of treatment, other drugs, compounds and / or materials used in combination with the specific composition used, the age, sex, weight, general health and previous medical history of the patient being treated, and similar factors well known in the medical field.

[0120] In certain preferred embodiments, the pharmaceutical composition further comprises one or more second therapeutic agents, which can be used to prevent and / or treat cancer.

[0121] In certain further preferred embodiments, the second therapeutic agent is a traditional cytotoxic anti-tumor drug and other anti-tumor immune drugs.

[0122] The present invention also provides the use of the compound of general formula I or its pharmaceutically acceptable salt, isomer, metabolite, solvate or prodrug, or pharmaceutical composition in the preparation of a drug for treating a disease or a vaccine adjuvant. The drug or vaccine adjuvant can be used to prevent and / or treat cancer or infectious diseases.

[0123] The present invention also provides the use of a compound of formula I or a pharmaceutically acceptable salt, isomer, metabolite, solvate or prodrug thereof, or a pharmaceutical composition in the preparation of a drug for activating the cGAS-STING pathway. The drug is a STING agonist.

[0124] The present invention also provides use of a compound of formula I or a pharmaceutically acceptable salt, isomer, metabolite, solvate or prodrug thereof, or a pharmaceutical composition thereof in the preparation of a drug for preventing and / or treating STING-related diseases.

[0125] The present invention also provides a compound of formula I or a pharmaceutically acceptable salt, isomer, metabolite, solvate or prodrug thereof, or a pharmaceutical composition and an immune checkpoint inhibitor for use in the preparation of an anti-tumor drug. The immune checkpoint inhibitor is a PD-1 / PD-L1 inhibitor, an IDO1 inhibitor and a CTLA-4 inhibitor. The compound of formula I of the present invention or a pharmaceutically acceptable salt, isomer, metabolite, solvate or prodrug thereof, or a pharmaceutical composition and an immune checkpoint inhibitor can be administered simultaneously or separately.

[0126] In the present invention, the tumor includes but is not limited to lung cancer, liver cancer, gastric cancer, breast cancer, melanoma, colorectal cancer, pancreatic cancer, prostate cancer, squamous cell carcinoma, glioma and leukemia.

[0127] Beneficial effects:

[0128] The compound of general formula I prepared by the present invention and its pharmaceutically acceptable salt, isomer, metabolite, solvate or prodrug have good agonist activity on the cGAS-STING pathway, and can provide a basis for the preparation of drugs that activate the cGAS-STING pathway. At the same time, the compound of the present invention has good activity in inducing THP1 cells to secrete IFNβ. Therefore, the above-mentioned compound can be used to prepare drugs for preventing and / or treating STING-related diseases, or combined with immune checkpoint inhibitors for the preparation of anti-tumor drugs. DETAILED DESCRIPTION

[0129] The technical solution of the present invention is described in detail below through specific examples, but the protection scope of the present invention is not limited to the examples. The raw materials and equipment used in the specific embodiments of the present invention are all known products, which are obtained by purchasing commercially available products. The present invention can be prepared in the form of salt by a salt-forming method commonly used in the art, for example: at room temperature, the compound is dissolved in hydrochloric acid ethanol for reaction to generate a hydrochloride; or benzenesulfonic acid is added thereto for reaction to generate a benzenesulfonate.

[0130] Intermediate Preparation Example 1

[0131]

[0132] Step 1: Preparation of 5-(benzyloxy)-2-bromo-4-methoxybenzaldehyde (3a)

[0133] 6.93g 2-bromo-5-hydroxy-4-methoxybenzaldehyde (1a, 30.0mmol), 8.28g potassium carbonate (60.0mmol) and 300mL DMF were added to a 1L reaction bottle, 6.12g benzyl bromide (36.0mmol) was added thereto, and the mixture was heated and stirred at 50°C for 2h. After the reaction of raw material 1a was complete as detected by TLC (petroleum ether: ethyl acetate = 1:1, v / v), the reaction solution was poured into 1.5L ice water. The filter cake was collected by suction filtration, and the filter cake was washed with water and dried to obtain a crude product. 200mL petroleum ether was added to the crude product and slurried at room temperature for 20min. After suction filtration, the filter cake was washed with petroleum ether and dried to obtain 9.24g of compound 3a as a white solid with a yield of 96%. 1 H NMR (300MHz, CDCl3): δ = 10.16 (s, 1H), 7.48 (s, 1H), 7.46–7.30 (m, 5H), 7.07 (s, 1H), 5.16 (s, 2H), 3.95 (s, 3H) ppm. HRMS(ESI + ): Calculated value C 15 H 14 BrO3 + (M+H) + ,321.0121; measured value 321.0125.

[0134] Step 2: Preparation of 5-(benzyloxy)-4-methoxy-2-(methylseleno)benzaldehyde (5a)

[0135] 9.63g of compound 3a (30.0mmol), 6.16g of DTT (dithiothreitol, 40.0mmol) and 100mL of DMF were added to a 500mL reaction bottle, and 3.76g of dimethyl diselenide (20.0mmol) and 7.60g of DBU (1,8-diazabicyclo[5.4.0]undec-7-ene, 50.0mmol) were added thereto. After stirring for 24h under nitrogen protection and room temperature, the reaction solution was poured into 500mL of water to precipitate. The filter cake was filtered and washed with water to obtain a crude product. The crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 8:1, v / v) to obtain 5.83g of compound 5a as a light yellow solid with a yield of 87%. 1 H NMR (300MHz, CDCl3): δ = 10.08 (s, 1H), 7.46–7.30 (m, 6H), 6.99 (s, 1H), 5.18 (s, 2H), 3.99 (s, 3H), 2.31 (s, 3H) ppm. HRMS(ESI + ): Calculated value C 16 H 17 O3Se + (M+H) +,337.0337; measured value 337.0339.

[0136] Step 3: Preparation of ethyl 2-((4-(benzyloxy)-2-formyl-5-methoxyphenyl)seleno)acetate (7a)

[0137] 6.70g of compound 5a (20.0mmol) and 50mL of DMF were added to a 250mL reaction bottle, and 10.02g of ethyl 2-bromoacetate (60.0mmol) was added. The reaction solution was heated and stirred at 150°C for 3.5h. After TLC detection (petroleum ether: ethyl acetate = 4:1, v / v) the raw material reaction was complete, the reaction solution was gradually cooled to room temperature. 250mL of water was added to dilute and extracted three times with 80mL of ethyl acetate. The organic phases were combined, washed with water, washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated to obtain a crude product of compound 7a as a brownish yellow solid. The crude product was directly used in the next step without additional purification.

[0138] HRMS(ESI + ): Calculated value C 19 H 21 5S + (M+H) + ,409.0549; measured value 409.0546.

[0139] Step 4: Preparation of ethyl 5-(benzyloxy)-6-methoxybenzo[b]selenophene-2-carboxylate (8a)

[0140] Compound 7a obtained in the previous step and 6.90g K2CO3 (50.0mmol) were added to a 250mL reaction bottle, and 70mL acetonitrile was added thereto. The reaction solution was stirred under reflux for 4h. After TLC detection (petroleum ether: ethyl acetate = 4:1, v / v) the raw materials reacted completely, and the reaction solution was gradually cooled to room temperature. After the reaction solution was concentrated, 300mL of water was added to dilute it, and it was extracted three times with 80mL of ethyl acetate. The organic phases were combined, washed with water, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 10:1, v / v) to obtain 5.91g of compound 8a, a light yellow solid, with a two-step yield of 76%. 1 H NMR (300MHz, DMSO-d6): δ = 8.24 (s, 1H), 7.74 (s, 1H), 7.68 (s, 1H), 7.50-7.32 (m, 5H), 5.12 (s, 2H), 4.33 (q, J = 6.9Hz, 2H), 3.86 (s, 3H), 1.33 (t, J = 7.0Hz, 3H) ppm. HRMS(ESI + ): Calculated value C 19 H19 oeLh + (M+H) + ,391.0443; measured value 391.0442.

[0141] Step 5: Preparation of 5-(Benzyloxy)-6-methoxybenzo[b]selenophene-2-carboxylic acid (9a)

[0142] 8.95g of compound 8a (23.0mmol), 90mL of methanol and 90mL of tetrahydrofuran were added to a 500mL reaction bottle, and 35mL of 2N aqueous sodium hydroxide solution was added. The reaction solution was stirred at 60°C for 1h. TLC detection (petroleum ether: ethyl acetate = 4:1, v / v) After the raw material reaction was complete, the reaction solvent was removed by decompression, and the resulting residue was adjusted to pH 2-3 with 1N HCl. After suction filtration, the filter cake was washed with water and dried to obtain 8.22g of compound 9a as an off-white solid with a yield of 99%. 1 H NMR (300MHz, DMSO-d6): δ = 8.16 (s, 1H), 7.73 (s, 1H), 7.66 (s, 1H), 7.50–7.32 (m, 5H), 5.12 (s, 2H), 3.85 (s, 3H) ppm. HRMS(ESI - ): Calculated value C 17 H 13 oeLh - (MH) - ,360.9985; measured value 360.9988.

[0143] Step 6: Preparation of methyl 3-(5-(benzyloxy)-6-methoxybenzo[b]selenophene-2-yl)-3-oxopropanoate (11a)

[0144] 9.03g of compound 9a (25.0mmol), 12.15g of CDI (N,N'-carbonyldiimidazole, 75.0mmol) and 180mL of DMF were added to a 500mL reaction bottle. The reaction solution was stirred at room temperature for 1h, and 7.13g of MgCl2 (75.0mmol) and 11.70g of potassium monomethyl malonate (75.0mmol) were added. The reaction was carried out at room temperature for 5h. After TLC detection (dichloromethane: methanol = 10:1, v / v), the raw materials reacted completely, and the reaction solution was poured into 900mL of water. The filter cake was filtered and washed with water to obtain a crude product. The crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 8:1, v / v) to obtain 8.76g of compound 11a as a yellow solid with a yield of 84%. 1H NMR (300MHz, CDCl3): δ = 8.02 (s, 1H), 7.48–7.31 (m, 7H), 5.21 (s, 2H), 3.98 (s, 3H), 3.97 (s, 2H), 3.76 (s, 3H) ppm. HRMS(ESI + ): Calculated value C 20 H 19 5S + (M+H) + ,419.0392; measured value 419.0390.

[0145] Intermediate Preparation Example 2

[0146]

[0147] Step 1: Preparation of methyl ethyl 2-(5-(benzyloxy)-6-methoxybenzo[b]selenophene-2-carbonyl)succinate (13a)

[0148] 2.09g of compound 11a (5.00mmol), 1.38g of K2CO3 (10.0mmol) and 20mL of DMF were added to a 100mL reaction bottle, and 1.00g of ethyl 2-bromoacetate (6.00mmol) was added. The reaction solution was stirred at room temperature for 4h, and TLC detection (petroleum ether: ethyl acetate = 4:1, v / v) was performed. After the raw material reaction was complete, 100mL of water was added to the reaction solution, and 40mL of ethyl acetate was extracted three times. The organic phases were combined, washed with water, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and the crude product of compound 13a was obtained. The crude product was directly used in the next step without additional purification.

[0149] HRMS(ESI + ): Calculated value C 24 H 25 7sE + (M+H) + ,505.0760; measured value 505.0759.

[0150] Step 2: Preparation of 4-(5-hydroxy-6-methoxybenzo[b]selenophene-2-yl)-4-oxobutanoic acid (14a)

[0151] Add compound 13a obtained in the previous step and 10 mL of acetic acid to a 100 mL reaction bottle, and slowly add 10 mL of concentrated hydrochloric acid. The resulting reaction solution was stirred at 90 ° C for 2 h. After TLC detection (petroleum ether: ethyl acetate = 4:1, v / v) the raw materials reacted completely, the reaction solution was naturally cooled to room temperature, 90 mL of water was added and extracted three times with 30 mL of ethyl acetate. The organic phases were combined, washed with water, washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography (dichloromethane: methanol = 30:1, v / v) to obtain 0.96 g of compound 14a as a light yellow solid, with a two-step yield of 59%. 1 H NMR (300MHz, DMSO-d6): δ = 12.16 (s, 1H), 9.36 (s, 1H), 8.39 (s, 1H), 7.63 (s, 1H) ), 7.36 (s, 1H), 3.86 (s, 3H), 3.26 (t, J = 6.1Hz, 2H), 2.60 (t, J = 6.3Hz, 2H) ppm. HRMS(ESI - ): Calculated value C 13 H 11 5S - (MH) - ,326.9777; measured value 326.9780.

[0152] Step 3: Preparation of ethyl 4-(5-hydroxy-6-methoxybenzo[b]selenophene-2-yl)-4-oxobutanoate (15a)

[0153] 500 mg of compound 14a (1.53 mmol) and 15 mL of anhydrous ethanol were added to a 100 mL reaction bottle and placed in an ice bath to cool. 546 mg of SOCl2 (4.59 mmol) was slowly dripped into the reaction solution at 0 °C, and the temperature was gradually restored to room temperature after the dripping was completed. Stir under reflux for 1 h. After TLC detection (dichloromethane: methanol = 10: 1, v / v) the raw materials were completely consumed, the reaction was naturally cooled to room temperature, the reaction solution was concentrated, 60 mL of water was added and extracted three times with 15 mL of ethyl acetate. The organic phases were combined, washed with water, washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 4: 1, v / v) to obtain 516 mg of compound 15a as an off-white solid with a yield of 95%. 1H NMR (300MHz, CDCl3): δ = 8.08 (s, 1H), 7.39 (s, 1H), 7.31 (s, 1H), 4.20 (q, J = 7.1Hz, 2H) ,3.99(s,3H),3.35(t,J=6.7Hz,2H),2.79(t,J=6.8Hz,2H),1.29(t,J=7.1Hz,3H)ppm. HRMS(ESI + ): Calculated value C 15 H 17 5S + (M+H) + ,357.0236; measured value 357.0233.

[0154] As shown in Table 1 below, intermediates 15b to 15o can be prepared according to the synthesis method of intermediate 15a above using corresponding starting materials and reactants.

[0155] Table 1 Intermediates 15b-15o

[0156]

[0157]

[0158] Intermediate Preparation Example 3

[0159]

[0160] Step 1: Preparation of 5-(benzyloxy)-6-methoxybenzo[b]selenophene (20a)

[0161] 3.61g of compound 9a (10.0mmol), 3.20g of copper powder (50.0mmol) and 40mL of quinoline were added to a 150mL reaction bottle, and the resulting mixture was stirred at 170°C for 2 hours. After the reaction of the raw materials was complete, the reaction solution was naturally cooled to room temperature, 115mL of 6N HCl was added, and 40mL of ethyl acetate was used for extraction three times. The organic phases were combined, washed with water, washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 4: 1, v / v) to obtain 2.57g of compound 20a as a white solid with a yield of 81%. 1 H NMR (300MHz, CDCl3): δ = 7.85 (d, J = 6.0Hz, 1H), 7.56-7.44 (m, 3H), 7.41-7.27 (m, 5H), 5.20 (s, 2H), 3.97 (s, 3H) ppm. HRMS(ESI + ): Calculated value C 16 H15 O2Se + ,(M+H) + ,319.0232; measured value 319.0236.

[0162] Step 2: Preparation of 2-(5-(Benzyloxy)-6-methoxybenzo[b]selenophene-2-carbonyl)cyclopropane-1-carboxylic acid (22a)

[0163] Add 0.71g 3-oxabicyclo[3.1.0]hexane-2,4-dione (21a, 6.31mmol), 1.26g anhydrous aluminum chloride (9.46mmol) and 30mL anhydrous dichloromethane to a 100mL dry reaction bottle and stir for 1h in an ice bath. Add 1.00g compound 20a (3.15mmol) in an ice bath, and after addition, transfer to room temperature and continue stirring for 12h. Add 150mL saturated ammonium chloride solution and extract three times with 40mL dichloromethane. Combine the organic phases, wash with water, wash with saturated brine, dry with anhydrous sodium sulfate, filter and concentrate to obtain a crude product. The crude product is purified by silica gel column chromatography (dichloromethane: methanol = 30: 1, v / v) to obtain 0.27g of compound 22a as a yellow solid with a yield of 20%. 1 H NMR (300MHz, CDCl3): δ = 7.98 (s, 1H), 7.52–7.31 (m, 7H), 5.22 (s, 2H), 3.96 (s, 3H), 3. 22(q,J=8.2Hz,1H),2.46(q,J=8.1Hz,1H),2.20-2.09(m,1H),1.58-1.48(m,1H)ppm. HRMS(ESI - ): Calculated value C 21 H 17 5S - ,(MH) - ,429.0247; measured value 429.0248.

[0164] Step 3: Preparation of 2-(5-hydroxy-6-methoxybenzo[b]selenophene-2-carbonyl)cyclopropane-1-carboxylic acid (23a)

[0165] 0.27 g of compound 22a (0.63 mmol), 27 mg of Pd / C and 20 mL of methanol were added to a 100 mL reaction bottle, and the air in the reaction bottle was replaced with hydrogen three times, and stirred at room temperature for 10 h. After the reaction of the raw materials was completed by TLC detection (dichloromethane: methanol = 10: 1, v / v), the filtrate was filtered through diatomaceous earth, and the filtrate was concentrated and dried to obtain 205 mg of compound 23a as a light yellow solid, with a yield of 96%. 1H NMR (300MHz, DMSO-d6): δ=12.12(s,1H),9.28(s,1H),8.16(s,1H),7.57(s,1H),7.31(s,1H),3.8 6(s,3H),3.20(q,J=8.2Hz,1H),2.41(q,J=8.1Hz,1H),2.19-2.10(m,1H),1.61-1.50(m,1H)ppm. HRMS(ESI - ): Calculated value C 14 H 11 5S - ,(MH) - ,338.9777; measured value 338.9773.

[0166] Step 4: Preparation of ethyl 2-(5-hydroxy-6-methoxybenzo[b]selenophene-2-carbonyl)cyclopropane-1-carboxylate (24a)

[0167] 205 mg of compound 23a (0.60 mmol) and 6 mL of anhydrous ethanol were added to a 50 mL reaction bottle and placed in an ice bath to cool. 216 mg of SOCl2 (1.81 mmol) was slowly dripped into the reaction solution at 0 °C, and the temperature was gradually restored to room temperature after the dripping was completed. Stir under reflux for 1 h. After TLC detection (dichloromethane: methanol = 10: 1, v / v) showed that the raw materials were completely consumed, the reaction was naturally cooled to room temperature, the reaction solution was concentrated, 40 mL of water was added and extracted three times with 15 mL of ethyl acetate. The organic phases were combined, washed with water, washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 4: 1, v / v) to obtain 213 mg of compound 24a as a light yellow solid with a yield of 96%. 1 H NMR (300MHz, CDCl3): δ = 8.10 (s, 1H), 7.37 (s, 1H), 7.32 (s, 1H), 4.19 (q, J = 7.2Hz, 2H), 3.97 (s, 3H), 3.24 (q,J=8.1Hz,1H),2.33(q,J=8.0Hz,1H),2.16-2.05(m,1H),1.55-1.44(m,1H),1.30(t,J=7.0Hz,3H)ppm. HRMS(ESI - ): Calculated value C 16 H 17 5S + ,(M+H) + ,369.0236; measured value 369.0233.

[0168] As shown in Table 2 below, intermediates 24b and 24c can be prepared according to the synthesis method of intermediate 24a above using the corresponding reactants.

[0169] Table 2 Intermediates 24b-24c

[0170]

[0171] Intermediate Preparation Example 4

[0172]

[0173] Step 1: Preparation of methyl 5-(benzyloxy)-6-methoxybenzo[b]thiophene-2-carboxylate (29a)

[0174] 6.42g of compound 3a (20.0mmol), 8.28g of K2CO3 (60.0mmol) and 70mL of DMF were added to a 250mL reaction bottle, and 3.18g of methyl thioglycolate (30.0mmol), 0.38g of cuprous iodide (2mmol) and 0.15g of diethylamine (2mmol) were added. The reaction mixture was heated at 60°C for 8h. TLC detection (petroleum ether: ethyl acetate = 4:1, v / v) showed that the raw materials reacted completely. After the reaction solution was cooled to room temperature, it was poured into 350mL of water. Filter by suction, wash the filter cake with water and dry it to obtain a crude product. The crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 8:1, v / v) to obtain 5.58g of compound 29a as a light yellow solid with a yield of 85%. 1 H NMR (300MHz, CDCl3): δ = 7.86 (s, 1H), 7.48-7.33 (m, 5H), 7.27 (s, 2H), 5.20 (s, 2H), 3.98 (s, 3H), 3.91 (s, 3H) ppm. HRMS(ESI + ): Calculated value C 18 H 17 O4S + ,(M+H) + ,329.0842; measured value 329.0845.

[0175] Step 2: Preparation of 5-(benzyloxy)-6-methoxybenzo[b]thiophene-2-carboxylic acid (30a)

[0176] 5.58 g of compound 29a (17.0 mmol), 70 mL of methanol and 70 mL of tetrahydrofuran were added to a 250 mL reaction bottle, and 25 mL of 2N NaOH aqueous solution was added. The reaction solution was stirred at 60°C for 1 h. After the reaction of the raw materials was completed by TLC detection (petroleum ether: ethyl acetate = 4:1, v / v), the reaction solvent was evaporated under reduced pressure, and the pH of the residue was adjusted to 2-3 with 1N HCl. After suction filtration, the filter cake was washed with water and dried to obtain 5.28 g of compound 30a as an off-white solid with a yield of 99%.

[0177] 1 H NMR (300MHz, DMSO-d6): δ=13.12(s,1H),7.88(s,1H),7.56(s,1H),7.54(s,1H),7.48-7.26(m,5H),5.10(s,2H),3.84(s,3H)ppm. HRMS(ESI - ): Calculated value C 17 H 13 O4S - ,(MH) - ,313.0540; measured value 313.0541.

[0178] Step 3: Preparation of methyl 3-(5-(benzyloxy)-6-methoxybenzo[b]thiophen-2-yl)-3-oxopropanoate (31a)

[0179] 4.71g of compound 30a (15.0mmol), 7.29g of CDI (45.0mmol) and 100mL of DMF were added to a 500mL reaction bottle. The resulting reaction solution was stirred at room temperature for 1h, and 4.28g of MgCl2 (45.0mmol) and 7.02g of potassium monomethyl malonate (45.0mmol) were added. The reaction was carried out at room temperature for 5h. After TLC detection (dichloromethane: methanol = 10: 1, v / v), the raw materials reacted completely, and the reaction solution was poured into 500mL of water. The filter cake was filtered and washed with water to obtain a crude product. The crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 8: 1, v / v) to obtain 4.27g of compound 31a as a yellow solid with a yield of 77%. 1 H NMR (300MHz, CDCl3): δ=7.87(s,1H),7.50-7.34(m,5H),7.28(s,2H),5.19(s,2H),3.98(s,3H),3.95(s,2H),3.71(s,3H)ppm. HRMS(ESI + ): Calculated value C 20 H 19 O5S + (M+H) +,371.0948; measured value 371.0947.

[0180] Step 4: Preparation of methyl ethyl 2-(5-(benzyloxy)-6-methoxybenzo[b]thiophene-2-carbonyl)succinate (32a)

[0181] 1.85g of compound 31a (5.0mmol), 1.38g of K2CO3 (10.0mmol) and 20mL of DMF were added to a 100mL reaction bottle, and 1.00g of ethyl 2-bromoacetate (6.0mmol) was added. The reaction solution was stirred at room temperature for 4h. After TLC (petroleum ether: ethyl acetate = 4:1, v / v) detected that the raw material reaction was complete, 100mL of water was added to the reaction solution, and extracted three times with 40mL of ethyl acetate. The organic phases were combined, washed with water, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and the crude product of compound 32a was obtained. The crude product was directly used in the next step without additional purification.

[0182] HRMS(ESI + ): Calculated value C 24 H 25 7S + (M+H) + ,457.1316; measured value 457.1318.

[0183] Step 5: Preparation of 4-(5-hydroxy-6-methoxybenzo[b]thiophen-2-yl)4-oxobutanoic acid (33a)

[0184] The compound 32a prepared in the previous step and 10 mL of acetic acid were added to a 100 mL reaction bottle, and 10 mL of concentrated hydrochloric acid was slowly added. The resulting reaction solution was stirred at 90 ° C for 2 h. After the reaction of the raw materials was complete, the reaction solution was gradually cooled to room temperature, 100 mL of water was added, and 30 mL of ethyl acetate was used for extraction three times. The organic phases were combined, washed with water, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography (dichloromethane: methanol = 30: 1, v / v) to obtain 0.94 g of compound 33a as a light yellow solid, with a two-step yield of 67%. 1 H NMR (300MHz, DMSO-d6): δ = 12.14 (s, 1H), 9.33 (s, 1H), 8.12 (s, 1H), 7.48 (s, 1H) ), 7.25 (s, 1H), 3.83 (s, 3H), 3.18 (t, J = 6.1Hz, 2H), 2.53 (t, J = 6.1Hz, 2H) ppm. HRMS(ESI - ): Calculated value C 13 H 11 O5S- (MH) - ,279.0333; measured value 279.0335.

[0185] Step 6: Preparation of ethyl 4-(5-hydroxy-6-methoxybenzo[b]thiophen-2-yl)4-oxobutanoate (34a)

[0186] 0.94g of compound 33a (3.36mmol) and 30mL of anhydrous ethanol were added to a 100mL reaction bottle and placed in an ice bath to cool. 1.20g of SOCl2 (10.07mmol) was slowly dripped at 0℃, and the reaction was moved to room temperature after the dripping was completed. After it returned to room temperature, it was stirred for 2h under reflux. After TLC detection (dichloromethane: methanol = 10: 1, v / v) the raw material reacted completely, the reaction solution was naturally cooled to room temperature, the solvent was evaporated under reduced pressure, 80mL of water was added and extracted three times with 20mL of ethyl acetate. The organic phases were combined, washed with water, washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 4: 1, v / v) to obtain 0.95g of compound 34a as a light yellow solid with a yield of 92%. 1 H NMR (300MHz, CDCl3): δ=7.92(s,1H),7.27(s,2H),4.17(q,J=7.3Hz,2H),3.97( s, 3H), 3.16 (t, J = 6.0Hz, 2H), 2.51 (t, J = 6.1Hz, 2H), 1.29 (t, J = 6.9Hz, 3H) ppm. HRMS(ESI + ): Calculated value C 15 H 17 O5S + (M+H) + ,309.0791; measured value 309.0791.

[0187] As shown in Table 3 below, intermediates 34b to 34f can be prepared according to the synthesis method of intermediate 34a above, using corresponding starting materials and reactants.

[0188] Table 3 Intermediates 34b-34f

[0189]

[0190]

[0191] Example 1 Preparation of 4,4'-((propane-1,3-diylbis(oxy))bis(6-methoxybenzo[b]selenophene-5,2-diyl))bis(4-oxobutyric acid diethyl ester) (C48)

[0192]

[0193] Step 1: Preparation of ethyl 4-(5-(3-bromopropyl)-6-methoxybenzo[b]selenophene-2-yl)-4-oxobutanoate (17a)

[0194] 258 mg of compound 15a (0.73 mmol), 201 mg of K2CO3 (1.45 mmol) and 7 mL of DMF were added to a 100 mL reaction bottle, and 1.47 g of 1,3-dibromopropane (7.27 mmol) was added. The reaction solution was stirred at 45 °C for 2 h. After the reaction of the raw material was complete, 50 mL of water was added for dilution, and 12 mL of ethyl acetate was used for extraction three times. The organic phases were combined, washed with water, washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 4:1) to obtain 263 mg of compound 17a as a light yellow solid with a yield of 76%. 1 H NMR (300MHz, CDCl3): δ = 8.11 (s, 1H), 7.34 (s, 1H), 7.33 (s, 1H), 4.23–4.13 (m, 4H), 3.95 (s, 3H), 3.69 (t, J=6.3Hz,2H),3.35(t,J=6.8Hz,2H),2.80(t,J=6.7Hz,2H),2.46–2.38(m,2H),1.29(t,J=7.1Hz,3H)ppm. HRMS(ESI + ): Calculated value C 18 H 22 BrO5Se + (M+H) + ,476.9810; measured value 476.9814.

[0195] Step 2: Preparation of 4,4'-((propane-1,3-diylbis(oxy))bis(6-methoxybenzo[b]selenophene-5,2-diyl))bis(4-oxobutanoic acid diethyl ester) (C48)

[0196] 250 mg of compound 17a (0.53 mmol), 186 mg of compound 15a (0.53 mmol), 217 mg of K2CO3 (1.58 mmol), 9 mg of KI (0.05 mmol), 14 mg of 18-crown ether-6 (0.05 mmol) and 6 mL of DMF were added to a 50 mL reaction bottle, and the resulting reaction solution was stirred at 50 ° C for 8 h. After TLC detection (petroleum ether: ethyl acetate = 4: 1, v / v) the raw materials reacted completely, 50 mL of water was added, and 12 mL of ethyl acetate was used for extraction three times. The organic phases were combined, washed with water, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 2: 1, v / v) to obtain 347 mg of compound C48 as a yellow solid with a yield of 88%.

[0197] 1 H NMR (300MHz, DMSO-d6): δ = 8.40 (s, 2H), 7.72 (s, 2H), 7.59 (s, 2H), 4.23 (t, J = 5.6Hz, 4H), 4.09 (q, J = 7.1Hz, 4 H), 3.85 (s, 6H), 3.31 (t, J = 5.8Hz, 4H), 2.68 (t, J = 6.2Hz, 4H), 2.33–2.27 (m, 2H), 1.20 (t, J = 7.1Hz, 6H) ppm.

[0198] 13 C NMR (75MHz, DMSO-d6): δ=191.17,170.83,148.93,146.29,143.08,136.28,135.6 0,133.25,110.76,109.04,66.01,59.90,56.14,32.98,29.18,28.68,15.52ppm.

[0199] HRMS(ESI + ): Calculated value C 33 H 37 O 10 Se2 + (M+H) + ,753.0712; measured value 753.0715.

[0200] Example 2 Preparation of 4,4'-((propane-1,3-diylbis(oxy))bis(6-methoxybenzo[b]selenophene-5,2-diyl))bis(4-oxobutanoic acid) (C1)

[0201]

[0202] 150 mg of compound 19a (0.20 mmol), 2 mL of methanol and 2 mL of tetrahydrofuran were added to a 50 mL reaction bottle, and 0.6 mL of 2N sodium hydroxide aqueous solution was added. The reaction solution was stirred at 55 °C for 1 h. After the reaction of the raw materials was complete, the reaction solution was concentrated, and the residue was adjusted to pH 2-3 with 1N HCl and extracted three times with 15 mL of ethyl acetate. The organic phases were combined, washed with water, washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography (dichloromethane: methanol = 30: 1, v / v) to obtain 98 mg of compound C1 as a yellow solid with a yield of 71%. 1 HNMR (300MHz, DMSO-d6): δ=12.19(s,2H),8.40(s,2H),7.71(s,2H),7.59(s,2H),4.23(t,J= 5.9Hz, 4H), 3.85 (s, 6H), 3.27 (t, J = 5.9Hz, 4H), 2.61 (t, J = 6.2Hz, 4H), 2.31–2.27 (m, 2H) ppm. 13 C NMR (75MHz, DMSO-d6): δ=194.04,174.20,150.99,147.94,145.12,137.39,135.52,134.61,110.74,108.60,65.63,56.34,33.01,29.08,28.50ppm. HRMS(ESI - ): Calculated value C 29 H 27 O 10 Se2 - (MH) - ,694.9940; measured value 694.9943.

[0203] Example 3 Preparation of 4,4'-((propane-1,3-diylbis(oxy))bis(6-methoxybenzo[b]selenophene-5,2-diyl))bis(2-methyl-4-oxobutanoic acid) (C2)

[0204]

[0205] Referring to the preparation methods described in Examples 1 and 2, two molecules of intermediate 15b were connected via 1,3-dibromopropane to prepare compound C2.

[0206] 1H NMR (300MHz, DMSO-d6): δ = 12.17 (s, 2H), 8.39 (s, 2H), 7.71 (s, 2H), 7.57 (s, 2H), 4.23 (t, J = 5.9Hz, 4H), 3.85 (s, 6H), 3.42-3.36 (m, 2H), 3.09-3.02 (m, 2H), 2.94-2.85 (m, 2H), 2.30 (t, J = 5.9Hz, 2H), 1.19 (d, J = 7.1Hz, 6H) ppm.

[0207] 13 C NMR (75MHz, DMSO-d6): δ=193.37,176.59,150.58,147.48,144.85,137.01,13 5.05,134.25,110.37,108.17,65.21,55.88,40.87,34.83,28.63,17.05ppm.

[0208] HRMS(ESI – ): Calculated value C 31 H 31 O 10 Se2 - ,(MH) - ,723.0253; measured value 723.0249.

[0209] Example 4 Preparation of 4,4'-((propane-1,3-diylbis(oxy))bis(6-methoxybenzo[b]selenophene-5,2-diyl))bis(2-ethyl-4-oxobutanoic acid) (C3)

[0210]

[0211] Referring to the preparation methods described in Examples 1 and 2, two molecules of intermediate 15c were connected via 1,3-dibromopropane to prepare compound C3.

[0212] 1 H NMR (300MHz, DMSO-d6): δ = 12.19 (s, 2H), 8.42 (s, 2H), 7.70 (s, 2H), 7.59 (s, 2H), 4.23 (t, J = 5.9Hz, 4H), 3.85 (s, 6H), 3.38 (dd, J1 = 17.4Hz, J2 =9.6Hz,2H),3.11(dd,J1=17.4Hz,J2=4.4Hz,2H),2.92-3.83(m,2H),2.30(t,J=5.7Hz,2H),1.62(p,J=6.6Hz,4H),0.95(t,J=7.4Hz,6H)ppm.

[0213] 13 C NMR (75MHz, DMSO-d6): δ=193.83,176.15,150.73,147.65,144.99,137.21,13 5.26,134.57,110.48,108.28,65.33,56.07,41.68,28.75,24.78,11.52ppm.

[0214] HRMS(ESI – ): Calculated value C 33 H 35 O 10 Se2 - ,(MH) - ,751.0566; measured value 751.0569.

[0215] Example 5 Preparation of 4,4'-((propane-1,3-diylbis(oxy))bis(6-methoxybenzo[b]selenophene-5,2-diyl))bis(2-isopropyl-4-oxobutanoic acid) (C4)

[0216]

[0217] Referring to the preparation methods described in Examples 1 and 2, two molecules of intermediate 15d were connected via 1,3-dibromopropane to prepare compound C4.

[0218] 1 H NMR (300MHz, DMSO-d6): δ = 12.20 (s, 2H), 8.45 (s, 2H), 7.71 (s, 2H), 7.60 (s, 2H), 4.22 (t, J = 6.0Hz, 4H), 3.84 (s, 6H), 3.43-3.37 (m, 2 H),3.10-3.01(m,2H),2.94-2.86(m,2H),2.31(t,J=5.8Hz,2H),2.20-2.15(m,2H),1.14(d,J=7.1Hz,6H),1.06(d,J=7.0Hz,6H)ppm. 13 C NMR (75MHz, DMSO-d6): δ=193.54,175.98,150.11,147.53,145.19,137.40,135.51,1 34.23,109.94,108.24,65.14,56.36,45.83,40.77,32.64,30.31,20.89,20.06ppm. HRMS(ESI – ): Calculated value C 35 H39 O 10 Se2 - ,(MH) - ,779.0879; measured value 779.0881.

[0219] Example 6 Preparation of 4,4'-((propane-1,3-diylbis(oxy))bis(6-methoxybenzo[b]selenophene-5,2-diyl))bis(2-cyclopropyl-4-oxobutanoic acid) (C5)

[0220]

[0221] Referring to the preparation method described in Examples 1 and 2, two molecules of intermediate 15e were connected via 1,3-dibromopropane to prepare compound C5. 1 H NMR (300MHz, DMSO-d6): δ=12.20(s,2H),8.42(s,2H),7.69(s,2H),7.62(s,2H),4.21(t,J=5.9Hz,4H),3.83(s,6H),3.41-3.35( m,2H),3.12-3.03(m,2H),2.95-2.85(m,2H),2.29(t,J=6.0Hz,2H),2.32-2.20(m,2H),1.66-1.55(m,4H),1.47-1.39(m,4H)ppm. 13 C NMR (75MHz, DMSO-d6): δ=192.88,176.17,150.34,148.10,145.25,137.82,136.03, 134.56,110.02,107.61,65.34,57.29,46.28,39.75,28.94,12.89,7.80,7.12ppm. HRMS(ESI – ): Calculated value C 35 H 35 O 10 Se2 - ,(MH) - ,775.0566; measured value 775.0567.

[0222] Example 7 Preparation of 4,4'-((propane-1,3-diylbis(oxy))bis(6-methoxybenzo[b]selenophene-5,2-diyl))bis(2-butyl-4-oxobutanoic acid) (C6)

[0223]

[0224] Referring to the preparation method described in Examples 1 and 2, two molecules of intermediate 15f were connected via 1,3-dibromopropane to prepare compound C6.

[0225] 1 H NMR (300MHz, DMSO-d6): δ=12.19(s,2H),8.43(s,2H),7.71(s,2H),7.61(s,2H),4.20(t,J=5.9Hz,4H),3.85(s,6H),3.39-3.33( m,2H),3.11-3.02(m,2H),2.91-2.85(m,2H),2.30(t,J=5.9Hz,2H),1.63-1.58(m,4H),1.35-1.27(m,8H),1.00-0.93(m,6H)ppm. 13 C NMR (75MHz, DMSO-d6): δ=195.01,177.22,150.58,146.97,145.35,137.28,135.49,134. 20,111.83,108.95,65.47,56.81,42.66,41.07,30.36,28.57,26.10,20.53,13.69ppm. HRMS(ESI – ): Calculated value C 37 H 43 O 10 Se2 - ,(MH) - ,807.1192; measured value 807.1191.

[0226] Example 8 Preparation of 4,4'-((propane-1,3-diylbis(oxy))bis(6-methoxybenzo[b]selenophene-5,2-diyl))bis(2-methoxymethyl-4-oxobutanoic acid) (C7)

[0227]

[0228] Referring to the preparation method described in Examples 1 and 2, two molecules of intermediate 15g were connected by 1,3-dibromopropane to prepare compound C7.

[0229] 1H NMR (300MHz, DMSO-d6): δ=12.21(s,2H),8.43(s,2H),7.71(s,2H),7.63(s,2H),4.23(t,J=5.8Hz,4H),3.83(s,6H),3 .62(d,J=6.3Hz,4H),3.42-3.36(m,2H),3.21(s,6H),3.11-3.04(m,2H),2.93-2.81(m,2H),2.30(t,J=5.9Hz,2H)ppm. 13 C NMR (75MHz, DMSO-d6): δ=194.27,174.86,151.29,148.54,145.06,137.00,136.1 1,134.84,110.57,108.16,73.91,64.97,59.05,56.13,42.75,39.30,29.44ppm. HRMS(ESI – ): Calculated value C 33 H 35 O 12 Se2 - ,(MH) - ,783.0464; measured value 783.0464.

[0230] Example 9 Preparation of 2,2'-(5,5'-(propane-1,3-diylbis(oxy)bis(6-methoxybenzo[b]selenophene-5,2-diyl-2-carbonyl))bis(cyclopropane-1-carboxylic acid) (C8)

[0231]

[0232] Referring to the preparation method described in Examples 1 and 2, two molecules of intermediate 24a were connected via 1,3-dibromopropane to prepare compound C8.

[0233] 1 H NMR (300MHz, DMSO-d6): δ = 12.20 (s, 2H), 8.42 (s, 2H), 7.70 (s, 2H), 7.62 (s, 2H), 4.20 (t, J = 5.8Hz, 4 H),3.84(s,6H),3.50-3.41(m,2H),2.30(t,J=6.0Hz,2H),2.25-2.17(m,2H),1.77-1.55(m,4H)ppm. 13C NMR (75MHz, DMSO-d6): δ=193.51,173.70,150.68,147.93,144.37,137.55,13 5.42,134.27,111.58,108.73,64.32,56.59,33.71,30.49,21.30,14.82ppm. HRMS(ESI – ): Calculated value C 31 H 27 O 10 Se2 - ,(MH) - ,718.9940; measured value 718.9937.

[0234] Example 10 Preparation of 2,2'-(5,5'-(propane-1,3-diylbis(oxy)bis(6-methoxybenzo[b]selenophene-5,2-diyl-2-carbonyl))bis(cyclobutane-1-carboxylic acid) (C9)

[0235]

[0236] Referring to the preparation method described in Examples 1 and 2, two molecules of intermediate 24b were connected via 1,3-dibromopropane to prepare compound C9.

[0237] 1 H NMR (300MHz, DMSO-d6): δ=12.19(s,2H),8.38(s,2H),7.69(s,2H),7.58(s,2H),4.23(t,J =5.9Hz,4H),3.84(s,6H),3.23-3.06(m,4H),2.29(t,J=6.0Hz,2H),2.19-2.01(m,8H)ppm. 13 C NMR (75MHz, DMSO-d6): δ=194.03,174.16,151.22,147.95,144.66,137.26,135.3 0,134.53,110.12,108.74,64.43,56.23,50.16,44.61,29.83,25.37,24.62ppm. HRMS(ESI – ): Calculated value C 33 H 31 O 10 Se2 - ,(MH) - ,747.0253; measured value 747.0251.

[0238] Example 11 Preparation of 2,2'-(5,5'-(propane-1,3-diylbis(oxy)bis(6-methoxybenzo[b]selenophene-5,2-diyl-2-carbonyl))bis(cyclohexane-1-carboxylic acid) (C10)

[0239]

[0240] Referring to the preparation methods described in Examples 1 and 2, two molecules of intermediate 24c were connected via 1,3-dibromopropane to prepare compound C10.

[0241] 1 H NMR (300MHz, DMSO-d6): δ=12.19(s,2H),8.40(s,2H),7.70(s,2H),7.58(s,2H),4.22(t,J= 5.9Hz, 4H), 3.83 (s, 6H), 2.79-2.67 (m, 4H), 2.30 (t, J = 6.0Hz, 2H), 1.81-1.63 (m, 16H) ppm. 13 C NMR (75MHz, DMSO-d6): δ=194.29,174.54,150.75,147.67,145.00,137.73,136.17,134. 99,109.84,108.31,63.15,56.34,51.96,48.30,29.66,27.49,25.82,25.17,24.67ppm. HRMS(ESI – ):cacld for C 37 H 39 O 10 Se2 - ,(MH) - ,803.0879;found803.0876.

[0242] Example 12 Preparation of 4,4'-((propane-1,3-diylbis(oxy))bis(5-methoxybenzo[b]selenophene-6,2-diyl))bis(4-oxobutanoic acid) (C11)

[0243]

[0244] Referring to the preparation method described in Examples 1 and 2, two molecules of intermediate 15h were connected via 1,3-dibromopropane to prepare compound C11. 1H NMR (300MHz, DMSO-d6): δ=12.18(s,2H),8.42(s,2H),7.76(s,2H),7.53(s,2H),4.26(t,J=6 .0Hz,4H),3.83(s,6H),3.27(t,J=6.0Hz,4H),2.61(t,J=6.2Hz,4H),2.31-2.27(m,2H)ppm. 13 C NMR (75MHz, DMSO-d6): δ=193.55,173.67,149.44,148.47,144.73,136.64,135.17,134.12,109.16,108.95,65.16,55.66,32.55,28.49,28.06ppm. HRMS(ESI - ): Calculated value C 29 H 27 O 10 Se2 - (MH) - ,694.9940; measured value 694.9942.

[0245] Example 13 Preparation of 4,4'-((propane-1,3-diylbis(oxy))bis(5-methoxybenzo[b]selenophene-6,2-diyl))bis(2-methyl-4-oxobutanoic acid) (C12)

[0246]

[0247] Referring to the preparation methods described in Examples 1 and 2, two molecules of intermediate 15i were connected via 1,3-dibromopropane to prepare compound C12.

[0248] 1 H NMR (300MHz, DMSO-d6): δ = 12.16 (s, 2H), 8.41 (s, 2H), 7.75 (s, 2H), 7.51 (s, 2H), 4.25 (d, J = 5.7Hz, 4H), 3.82 (s, 6H), 3.4 2–3.36(m,2H),3.10(d,J1=17.1Hz,J2=5.1Hz,2H),2.91–2.84(m,2H),2.30(t,J=5.9Hz,2H),1.19(d,J=7.2Hz,6H)ppm. 13C NMR (75MHz, DMSO-d6): δ=193.86,177.04,149.93,148.93,145.40,137.19,13 5.63,134.73,109.62,109.41,65.61,56.12,41.33,35.29,28.94,17.50ppm. HRMS(ESI – ): Calculated value C 31 H 31 O 10 Se2 - ,(MH) - ,723.0253; measured value 723.0254.

[0249] Example 14 Preparation of 4,4'-((propane-1,3-diylbis(oxy))bis(5-methoxybenzo[b]selenophene-6,2-diyl))bis(2-ethyl-4-oxobutanoic acid) (C13)

[0250]

[0251] Referring to the preparation method described in Examples 1 and 2, two molecules of intermediate 15j were connected via 1,3-dibromopropane to prepare compound C13.

[0252] 1 H NMR (300MHz, DMSO-d6): δ=12.18(s,2H),8.44(s,2H),7.75(s,2H),7.52(s,2H),4.26(t,J=5.4Hz,4H),3.82(s,6H),3.4 2-3.36(m,2H),3.11-3.03(m,2H),2.82-2.73(m,2H),2.31(t,J=5.7Hz,2H),1.69-.54(m,4H),0.95(t,J=7.4Hz,6H)ppm. 13 C NMR (75MHz, DMSO-d6): δ=193.58,175.93,149.47,148.48,144.94,136.75,13 5.19,134.36,109.16,108.96,65.15,55.66,41.58,28.49,24.60,11.33ppm. HRMS(ESI – ): Calculated value C 33 H 35 O 10 Se2 - ,(MH) - ,751.0566; measured value 751.0566.

[0253] Example 15 Preparation of 4-(5-(3-((2-(3-carboxypropionyl)-6-methoxybenzo[b]selenophene-5-yl)oxy)propoxy)-6-methoxybenzo[b]selenophene-2-yl)-2-methyl-4-oxobutanoic acid (C14)

[0254]

[0255] Referring to the preparation methods described in Examples 1 and 2, one molecule of intermediate 15a and one molecule of intermediate 15b were connected via 1,3-dibromopropane to prepare compound C14. 1 H NMR (300MHz, DMSO-d6): δ = 12.17 (s, 2H), 8.39 (s, 2H), 7.69 (s, 2H), 7.59 (s, 2H), 4.23 (t, J = 5.8Hz, 4H), 3.85 (s, 6H),3.40-3.32(m,2H),3.18-3.06(m,2H),2.77-2.60(m,3H),2.29(t,J=5.9Hz,2H),1.19(d,J=7.2Hz,3H)ppm. 13 CNMR (75MHz, DMSO-d6): δ = 193.65, 193.49, 176.72, 173.81, 150.65, 150.61, 147.57, 144.94, 144.74, 137. 10,137.00,135.15,134.39,134.24,110.37,108.24,65.26,55.97,40.95,32.63,28.70,28.13,17.16ppm. HRMS(ESI – ): Calculated value C 30 H 29 O 10 Se2 - ,(MH) - ,709.0097; measured value 709.0098.

[0256] Example 16 Preparation of 4-(5-(3-((2-(3-carboxypropanoyl)-6-methoxybenzo[b]selenophene-5-yl)oxy)propoxy)-6-methoxybenzo[b]selenophene-2-yl)-2-ethyl-4-oxobutanoic acid (C15)

[0257]

[0258] Referring to the preparation methods described in Examples 1 and 2, one molecule of intermediate 15a and one molecule of intermediate 15c were connected via 1,3-dibromopropane to prepare compound C15. 1H NMR (300MHz, DMSO-d6): δ = 12.18 (s, 2H), 8.41 (s, 2H), 7.71 (s, 2H), 7.57 (s 2H),4.22(t,J=6.0Hz,4H),3.83(s,6H),3.46-3.37(m,2H),3.17-3.08(m,2H),2.6 7-2.57(m,3H),2.27(t,J=5.9Hz,2H),1.65-1.54(m,2H),0.94(t,J=7.5Hz,3H)ppm. 13 C NMR (75MHz, DMSO-d6): δ=195.27,194.59,174.63,173.39,150.84,150.42,146.90,145.00,144.83,137.23,137. 16,135.18,134.76,134.50,110.92,108.97,65.21,55.66,43.63,42.75,39.24,30.10,28.79,25.18,12.86ppm. HRMS(ESI – ): Calculated value C 31 H 31 O 10 Se2 - ,(MH) - ,723.0253; measured value 723.0257.

[0259] Example 17 Preparation of 2-(5-(3-((2-(3-carboxypropanoyl)-6-methoxybenzo[b]selenophene-5-yl)oxy)propoxy)-6-methoxybenzo[b]selenophene-2-carbonyl)cyclobutane-1-carboxylic acid (C16)

[0260]

[0261] Referring to the preparation methods described in Examples 1 and 2, one molecule of intermediate 15a and one molecule of intermediate 24b were connected via 1,3-dibromopropane to prepare compound C16. 1 H NMR (300MHz, DMSO-d6): δ = 12.20 (s, 2H), 8.44 (s, 2H), 7.69 (s, 2H), 7.55 (s 2H),4.24(t,J=6.0Hz,4H),3.84(s,6H),3.45-3.32(m,1H),3.19-3.08(m,1H),3. 07-3.03(m,2H),2.63-2.56(m,2H),2.33(t,J=6.0Hz,2H),2.21-2.02(m,4H)ppm. 13C NMR (75MHz, DMSO-d6): δ=194.06,193.03,175.19,174.20,150.41,150.28,145.99,145.15,144.61,138.34,137. 94,135.83,134.49,134.14,111.07,107.89,65.65,56.78,52.94,44.48,37.61,30.45,29.88,24.95,22.17ppm. HRMS(ESI – ): Calculated value C 31 H 29 O 10 Se2 - ,(MH) - ,721.0097; measured value 721.0099.

[0262] Example 18 Preparation of 2-(5-(3-((2-(3-carboxypentanoyl)-6-methoxybenzo[b]selenophene-5-yl)oxy)propoxy)-6-methoxybenzo[b]selenophene-2-carbonyl)cyclobutane-1-carboxylic acid (C17)

[0263]

[0264] Referring to the preparation methods described in Examples 1 and 2, one molecule of intermediate 15c and one molecule of intermediate 24b were connected via 1,3-dibromopropane to prepare compound C17.

[0265] 1 H NMR (300MHz, DMSO-d6): δ=12.17(s,2H),8.45(s,2H),7.71(s,2H),7.57(s2H),4.20(t,J=6.0Hz,4H),3.83(s,6H),3.46-3.35(m,1H),3.12 -3.04(m,1H),3.09-3.03(m,2H),2.69-2.60(m,1H),2.31(t,J=6.1Hz,2H),2.20-2.00(m,4H),1.65-1.54(m,2H),0.95(t,J=7.3Hz,3H)ppm. 13C NMR (75MHz, DMSO-d6): δ=194.21,193.85,175.36,174.61,150.68,150.02,145.72,145.05,144.17,138.19,137.63, 135.84,134.90,134.57,111.49,107.41,65.39,56.27,50.52,43.92,42.47,41.71,30.94,24.72,23.00,11.95ppm. HRMS(ESI – ): Calculated value C 33 H 33 O 10 Se2 - ,(MH) - ,749.0410; measured value 749.0412.

[0266] Example 19 Preparation of 4-(6-(3-((2-(3-carboxypropanoyl)-5-methoxybenzo[b]selenophene-6-yl)oxy)propoxy)-5-methoxybenzo[b]thiophen-2-yl)-4-oxobutanoic acid (C18)

[0267]

[0268] Referring to the preparation methods described in Examples 1 and 2, one molecule of intermediate 15h and one molecule of intermediate 34d were connected via 1,3-dibromopropane to prepare compound C18. 1 H NMR (300MHz, DMSO-d6): δ=12.19(s,1H),12.13(s,1H),8.41(s,1H),7.95(s,1H),7.54(s,1H),7.32(s,1H),7.21(s,1H),7.06(s,1H),4.23(t ,J=6.1Hz,4H),3.84(s,6H),3.41(t,J=6.1Hz,2H),3.11(t,J=6.0Hz,2H),2.75(t,J=5.9Hz,2H),2.61(t,J=6.1Hz,2H),2.35-2.20(m,2H)ppm. 13C NMR (75MHz, DMSO-d6): δ=195.31,194.81,174.73,151.29,151.38,148.03,147.59,144.94,140.69,137.42,136.39,1 35.26,134.07,133.43,130.28,109.47,108.74,108.33,104.60,68.88,56.36,37.86,36.92,30.51,29.93,29.01ppm. HRMS(ESI – ): Calculated value C 29 H 27 O 10 SSe - ,(MH) - ,647.0496; measured value 647.0499.

[0269] Example 20 Preparation of 4-(6-(3-((2-(3-carboxybutyryl)-5-methoxybenzo[b]selenophene-6-yl)oxy)propoxy)-5-methoxybenzo[b]thiophen-2-yl)-2-methyl-4-oxobutanoic acid (C19)

[0270]

[0271] Referring to the preparation method described in Examples 1 and 2, one molecule of intermediate 15i and one molecule of intermediate 34e were connected via 1,3-dibromopropane to prepare compound C19. 1 H NMR (300MHz, DMSO-d6): δ=12.20(s,1H),12.11(s,1H),8.44(s,1H),7.98(s,1H),7.55(s,1H),7.32(s,1H),7.22(s,1H),7.03(s,1H),4.22(t,J =6.1Hz,4H),3.83(s,6H),3.40-3.35(m,2H),3.09-3.05(m,2H),2.78-2.65(m,2H),2.35-2.21(m,2H),1.18(dd,J1=10.5Hz,J2=4.7Hz,6H)ppm. 13C NMR (75MHz, DMSO-d6): δ=195.44,194.83,174.47,151.36,151.11,148.63,147.17,144.84,140.81,137.72,136.10,135.55, 134.53,133.14,130.19,109.31,108.74,108.26,104.35,68.61,56.70,45.90,43.02,37.84,35.23,29.95,17.62,17.31ppm. HRMS(ESI – ): Calculated value C 31 H 31 O 10 SSe - ,(MH) - ,675.0809; measured value 675.0811.

[0272] Example 21 Preparation of 4-(6-(3-((2-(3-carboxypentanoyl)-5-methoxybenzo[b]selenophene-6-yl)oxy)propoxy)-5-methoxybenzo[b]thiophen-2-yl)-2-ethyl-4-oxobutanoic acid (C20)

[0273]

[0274] Referring to the preparation methods described in Examples 1 and 2, one molecule of intermediate 15j and one molecule of intermediate 34f were connected via 1,3-dibromopropane to prepare compound C20. 1 H NMR (300MHz, DMSO-d6): δ = 12.18 (s, 1H), 12.13 (s, 1H), 8.42 (s, 1H), 7.97 (s, 1H),7.55(s,1H),7.33(s,1H),7.21(s,1H),7.02(s,1H),4.20(t,J=5.9Hz,4 H),3.84(s,6H),3.43-3.35(m,2H),3.12-3.06(m,2H),2.77-2.60(m,2H),2. 37-2.19(m,2H),1.65-1.57(m,4H),0.96(dt,J1=10.7Hz,J2=2.9Hz,6H)ppm. 13C NMR (75MHz, DMSO-d6): δ=195.27,194.77,174.04,151.86,151.32,148.47,147.74,144.06,140.90,137.21,136.69,135.55,134.62 ,133.34,130.24,109.03,108.73,108.11,104.33,68.14,56.67,43.08,42.64,41.31,40.09,30.39,24.57,24.06,11.77,11.34ppm. HRMS(ESI – ): Calculated value C 33 H 35 O 10 SSe - ,(MH) - ,703.1122; measured value 703.1120.

[0275] Example 22 Preparation of 4-(5-(3-((2-(3-carboxypropanoyl)-6-methoxybenzo[b]selenophene-5-yl)oxy)propoxy)-6-methoxybenzo[b]thiophen-2-yl)-4-oxobutanoic acid (C21)

[0276]

[0277] Referring to the preparation methods described in Examples 1 and 2, one molecule of intermediate 15a and one molecule of intermediate 34a were connected via 1,3-dibromopropane to prepare compound C21. 1 H NMR (300MHz, DMSO-d6): δ=12.23(s,1H),12.11(s,1H),8.45(s,1H),7.91(s,1H),7.40(s,1H),7.29(s,1H),7.21(s,1H),7.09(s,1H),4.21(t ,J=6.2Hz,4H),3.85(s,6H),3.42(t,J=6.1Hz,2H),3.10(t,J=6.0Hz,2H),2.77(t,J=5.9Hz,2H),2.62(t,J=6.1Hz,2H),2.32-2.23(m,2H)ppm. 13C NMR (75MHz, DMSO-d6): δ=194.82,194.63,174.47,151.69,151.14,148.01,147.21,144.41,140.86,137.91,136.19,1 35.71,134.16,133.39,130.77,110.17,109.97,108.28,104.25,68.40,56.33,37.72,36.51,30.20,29.60,29.18ppm. HRMS(ESI – ): Calculated value C 29 H 27 O 10 SSe - ,(MH) - ,647.0496; measured value 647.0495.

[0278] Example 23 Preparation of 4-(5-(3-((2-(3-carboxybutanoyl)-6-methoxybenzo[b]selenophene-5-yl)oxy)propoxy)-6-methoxybenzo[b]thiophen-2-yl)-2-methyl-4-oxobutanoic acid (C22)

[0279]

[0280] Referring to the preparation methods described in Examples 1 and 2, one molecule of intermediate 15b and one molecule of intermediate 34b were connected via 1,3-dibromopropane to prepare compound C22. 1 H NMR (300MHz, DMSO-d6): δ=12.23(s,1H),12.11(s,1H),8.45(s,1H),7.91(s,1H),7.40(s,1H),7.29(s,1H),7.21(s,1H),7.09(s,1H),4.21(t,J =6.1Hz,4H),3.85(s,6H),3.46-3.39(m,2H),3.11-3.04(m,2H),2.77-2.65(m,2H),2.33-2.20(m,2H),1.19(dd,J1=10.7Hz,J2=4.8Hz,6H)ppm. 13C NMR (75MHz, DMSO-d6): δ=194.84,194.10,174.26,151.31,151.09,148.67,147.65,144.64,140.50,137.93,136.55,135.24, 134.60,133.44,130.37,110.79,109.32,108.47,104.29,68.03,56.71,45.51,43.95,37.69,35.31,29.88,17.90,17,74ppm. HRMS(ESI – ): Calculated value C 31 H 31 O 10 SSe - ,(MH) - ,675.0809; measured value 675.0810.

[0281] Example 24 Preparation of 4-(5-(3-((2-(3-carboxypentanoyl)-6-methoxybenzo[b]selenophene-5-yl)oxy)propoxy)-6-methoxybenzo[b]thiophen-2-yl)-2-ethyl-4-oxobutanoic acid (C23)

[0282]

[0283] Referring to the preparation methods described in Examples 1 and 2, one molecule of intermediate 15c and one molecule of intermediate 34c were connected via 1,3-dibromopropane to prepare compound C23. 1 H NMR (300MHz, DMSO-d6): δ=12.22(s,1H),12.12(s,1H),8.41(s,1H),7.92(s, 1H),7.39(s,1H),7.28(s,1H),7.20(s,1H),7.06(s,1H),4.22(t,J=6.0Hz,4 H),3.85(s,6H),3.43-3.36(m,2H),3.11-3.06(m,2H),2.75-2.60(m,2H),2. 37-2.20(m,2H),1.67-1.57(m,4H),0.96(dt,J1=10.3Hz,J2=3.3Hz,6H)ppm.

[0284] 13C NMR (75MHz, DMSO-d6): δ=194.94,194.29,175.15,151.70,150.86,148.65,147.19,145.62,140.35,137.61,136.63,135.00,134.22 ,133.05,131.78,110.06,109.14,108.39,104.45,68.75,56.74,43.11,42.23,41.79,40.06,30.55,24.89,24.56,11.49,11.22ppm. HRMS(ESI – ): Calculated value C 33 H 35 O 10 SSe - ,(MH) - ,703.1122; measured value 703.1119.

[0285] Example 25 Preparation of 4-(5-(3-((2-(3-carboxypropanoyl)-6-methoxybenzo[b]thiophen-5-yl)oxy)propoxy)-6-methoxybenzo[b]selenophene-2-yl)-2-methyl-4-oxobutanoic acid (C24)

[0286]

[0287] Referring to the preparation methods described in Examples 1 and 2, one molecule of intermediate 15b and one molecule of intermediate 34a were connected via 1,3-dibromopropane to prepare compound C24. 1 H NMR (300MHz, DMSO-d6): δ = 12.19 (s, 1H), 12.13 (s, 1H), 8.44 (s, 1H), 7.95 (s,1H),7.54(s,1H),7.32(s,1H),7.21(s,1H),7.06(s,1H),4.23(t,J=6. 1Hz,4H),3.84(s,6H),3.47(t,J=6.3Hz,2H),3.45-3.37(m,1H),3.12-3.0 7(m,1H),2.75-2.66(m,3H),2.32-2.23(m,2H),1.19(d,J=6.9Hz,3H)ppm. 13C NMR (75MHz, DMSO-d6): δ=194.51,194.23,175.85,151.57,150.20,148.98,147.39,145.29,140.63,137.96,136.86,135. 42,134.79,133.83,131.40,110.11,109.22,108.05,104.60,68.92,56.02,45.75,36.53,36.18,30.50,29.96,18.30ppm. HRMS(ESI – ): Calculated value C 30 H 29 O 10 SSe - ,(MH) - ,661.0652; measured value 661.0651.

[0288] Example 26 Preparation of 4-(5-(3-((2-(3-carboxypropanoyl)-6-methoxybenzo[b]thiophen-5-yl)oxy)propoxy)-6-methoxybenzo[b]selenophene-2-yl)-2-ethyl-4-oxobutanoic acid (C25)

[0289]

[0290] Referring to the preparation methods described in Examples 1 and 2, one molecule of intermediate 15c and one molecule of intermediate 34a were connected via 1,3-dibromopropane to prepare compound C25. 1 H NMR (300MHz, DMSO-d6): δ=12.19(s,1H),12.13(s,1H),8.43(s,1H),7.95(s,1 H),7.54(s,1H),7.32(s,1H),7.21(s,1H),7.06(s,1H),4.23(t,J=6.1Hz,4H), 3.84(s,6H),3.49(t,J=6.3Hz,2H),3.49-3.40(m,1H),3.17-3.13(m,1H),2.77 -2.61(m,3H),2.37-2.19(m,2H),1.65-1.56(m,2H),0.94(t,J=7.3Hz,3H)ppm. 13C NMR (75MHz, DMSO-d6): δ=194.86,194.34,175.47,151.72,150.58,148.71,147.20,145.68,141.06,137.45,136.90,135.02, 134.60,134.09,131.77,109.27,109.15,108.08,104.05,68.64,56.10,43.87,41.48,39.00,30.80,30.28,25.99,12.54ppm. HRMS(ESI – ): Calculated value C 31 H 31 O 10 SSe - ,(MH) - ,675.0809; measured value 675.0805.

[0291] Example 27 Preparation of 4-(5-(3-((2-(3-carboxypropanoyl)-5-methoxybenzo[b]selenophene-6-yl)oxy)propoxy)-6-methoxybenzo[b]selenophene-2-yl)-4-oxobutanoic acid (C26)

[0292]

[0293] Referring to the preparation methods described in Examples 1 and 2, one molecule of intermediate 15a and one molecule of intermediate 15h were connected via 1,3-dibromopropane to prepare compound C26. 1 H NMR (300MHz, DMSO-d6): δ=12.24(s,1H),12.19(s,1H),8.42(s,1H),8.39(s,1H),7.76(s,1H),7.71(s,1H),7.58(s,1H),7.53(s,1H) ,4.27(dt,J1=14.7Hz,J2=5.1Hz,4H),3.84(s,3H),3.82(s,3H),3.27(t,J=6.5Hz,4H),2.61(t,J=6.1Hz,4H),2.30-2.26(m,2H)ppm. 13C NMR (75MHz, DMSO-d6): δ=193.67,173.99,150.49,149.46,148.48,147.45,144.82,144.73,136.93,136.67,135. 19,135.06,134.16,110.24,109.13,108.94,108.16,65.22,65.07,55.90,55.67,32.66,32.33,28.57,28.27ppm. HRMS(ESI – ): Calculated value C 29 H 27 O 10 Se2 - ,(MH) - ,694.9940; Found 694.9937. Example 28 Preparation of 4-(5-(3-((2-(3-carboxypropanoyl)-5-methoxybenzo[b]selenophene-6-yl)oxy)propoxy)-6-methoxybenzo[b]thiophene-2-yl)-4-oxobutanoic acid (C27)

[0294]

[0295] Referring to the preparation method described in Examples 1 and 2, one molecule of intermediate 15h and one molecule of intermediate 34a were connected via 1,3-dibromopropane to prepare compound C27. 1 H NMR (300MHz, DMSO-d6): δ = 12.19 (s, 1H), 12.10 (s, 1H), 8.40 (s, 1H), 7.97 (s,1H),7.40(s,1H),7.30(s,1H),7.22(s,1H),7.06(s,1H),4.22-4.16( m,2H),3.86(s,3H),3.84(s,3H),3.44(t,J=5.9Hz,2H),3.11(t,J=6.0Hz ,2H),2.72(t,J=5.8Hz,2H),2.61(t,J=5.9Hz,2H),2.31-2.26(m,2H)ppm. 13C NMR (75MHz, DMSO-d6): δ=195.22,194.48,178.51,153.04,152.64,148.06,147.79,145.95,141.59,137.06,136.44,135.84, 134.55,133.54,132.64,110.98,109.73,108.37,104.05,68.40,68.02,56.64,56.37,37.62,36.74,30.59,29.81,29.29ppm. HRMS(ESI – ): Calculated value C 29 H 27 O 10 SSe - ,(MH) - ,647.0496; measured value 647.0499.

[0296] Example 29 Preparation of 4-(5-(3-((2-(3-carboxypropanoyl)-5-methoxybenzo[b]thiophen-6-yl)oxy)propoxy)-6-methoxybenzo[b]selenophene-2-yl)-4-oxobutanoic acid (C28)

[0297]

[0298] Referring to the preparation methods described in Examples 1 and 2, one molecule of intermediate 15a and one molecule of intermediate 34d were connected via 1,3-dibromopropane to prepare compound C28. 1 H NMR (300MHz, DMSO-d6): δ = 12.24 (s, 1H), 12.13 (s, 1H), 8.42 (s, 1H), 7.96 (s,1H),7.41(s,1H),7.30(s,1H),7.21(s,1H),7.07(s,1H),4.22-4.17( m,2H),3.85(s,3H),3.84(s,3H),3.47(t,J=5.9Hz,2H),3.10(t,J=6.0Hz ,2H),2.78(t,J=5.8Hz,2H),2.65(t,J=5.9Hz,2H),2.32-2.24(m,2H)ppm. 13C NMR (75MHz, DMSO-d6): δ=195.68,194.41,178.38,153.83,152.96,148.84,147.06,145.63,141.16,137.55,136.59,135.81, 134.09,133.12,132.37,110.81,109.07,108.27,104.75,68.45,68.08,56.69,56.25,37.00,36.03,30.73,29.91,29.13ppm. HRMS(ESI – ): Calculated value C 29 H 27 O 10 SSe - ,(MH) - ,647.0496; measured value 647.0498.

[0299] Example 30 Preparation of 4,4'-((ethane-1,2-diylbis(oxy))bis(6-methoxybenzo[b]selenophene-5,2-diyl))bis(4-oxobutanoic acid) (C29)

[0300]

[0301] Referring to the preparation method described in Examples 1 and 2, two molecules of intermediate 15a were connected via 1,2-dibromoethane to prepare compound C29. 1 H NMR (300MHz, DMSO-d6): δ = 12.19 (s, 2H), 8.41 (s, 2H), 7.73 (s, 2H), 7.64 (s, 2H) ), 4.41 (s, 4H), 3.86 (s, 6H), 3.28 (t, J = 6.0Hz, 4H), 2.62 (t, J = 6.0Hz, 4H) ppm. 13 C NMR (75MHz, DMSO-d6): δ=193.71,173.85,150.47,147.39,144.85,137.19,135.12,134.24,110.45,108.31,67.23,55.91,32.64,28.15ppm. HRMS(ESI – ): Calculated value C 28 H 25 O 10 Se2 - ,(MH) - ,680.9784; measured value 680.9781.

[0302] Example 31 Preparation of 4,4'-((butane-1,4-diylbis(oxy))bis(6-methoxybenzo[b]selenophene-5,2-diyl))bis(4-oxobutanoic acid) (C30)

[0303]

[0304] Referring to the preparation methods described in Examples 1 and 2, two molecules of intermediate 15a were connected via 1,4-dibromobutane to prepare compound C30.

[0305] 1 H NMR (300MHz, DMSO-d6): δ = 12.20 (s, 2H), 8.41 (s, 2H), 7.72 (s, 2H), 7.57 (s, 2H), 4.12 (t, J = 5. 9Hz, 4H), 3.84 (s, 6H), 3.26 (t, J = 5.9Hz, 4H), 2.61 (t, J = 6.1Hz, 4H), 1.96 (t, J = 5.3Hz, 4H) ppm. 13 C NMR (75MHz, DMSO-d6): δ=193.68,173.83,150.62,147.69,144.70,136.81,135 .15,134.26,110.11,108.15,68.15,55.95,32.64,28.17,25.56ppm.HRMS(ESI – ): Calculated value C 30 H 29 O 10 Se2 - ,(MH) - ,709.0097; measured value 709.0095.

[0306] Example 32 Preparation of 4,4'-((pentane-1,5-diylbis(oxy))bis(6-methoxybenzo[b]selenophene-5,2-diyl))bis(4-oxobutanoic acid) (C31)

[0307]

[0308] Referring to the preparation methods described in Examples 1 and 2, two molecules of intermediate 15a were connected via 1,5-dibromopentane to prepare compound C31.

[0309] 1H NMR (300MHz, DMSO-d6): δ=12.20(s,2H),8.42(s,2H),7.73(s,2H),7.57(s,2H),4.12(t,J=5 .9Hz, 4H), 3.84 (s, 6H), 3.30 (t, J = 6.0Hz, 4H), 2.64 (t, J = 6.1Hz, 4H), 1.75-1.56 (m, 6H) ppm. 13 C NMR (75MHz, DMSO-d6): δ=193.03,173.16,150.39,147.96,144.27,136.49,13 5.76,134.10,110.91,108.89,68.14,55.50,38.52,29.47,29.18,23.23ppm. HRMS(ESI – ): Calculated value C 31 H 31 O 10 Se2 - ,(MH) - ,723.0253; measured value 723.0251.

[0310] Example 33 Preparation of 4,4'-(((oxybis(ethane-2,1-diyl))bis(oxy))bis(6-methoxybenzo[b]selenophene-5,2-diyl))bis(4-oxobutanoic acid) (C32)

[0311]

[0312] Referring to the preparation method described in Examples 1 and 2, two molecules of intermediate 15a were connected via 2,2'-dibromodiethyl ether to prepare compound C32.

[0313] 1 H NMR (300MHz, DMSO-d6): δ = 12.20 (s, 2H), 8.43 (s, 2H), 7.70 (s, 2H), 7.58 (s, 2H), 4.17 (t, J = 5. 9Hz, 4H), 3.84 (s, 6H), 3.79 (t, J = 6.4Hz, 4H), 3.29 (t, J = 6.0Hz, 4H), 2.62 (t, J = 6.1Hz, 4H) ppm. 13 C NMR (75MHz, DMSO-d6): δ=193.33,173.56,150.94,147.68,144.83,136.19,135.06,134.54,110.42,108.32,71.60,68.56,55.57,37.40,29.17ppm. HRMS(ESI –): Calculated value C 30 H 29 O 11 Se2 - ,(MH) - ,725.0046; measured value 725.0044.

[0314] Example 34 Preparation of 4,4'-(((2-methylpropane-1,3-diyl)bis(oxy))bis(6-methoxybenzo[b]selenophene-5,2-diyl))bis(4-oxobutanoic acid) (C33)

[0315]

[0316] Referring to the preparation method described in Examples 1 and 2, two molecules of intermediate 15a were connected via 1,3-dibromo-2-methylpropane to prepare compound C33. 1 H NMR (300MHz, DMSO-d6): δ=12.19(s,2H),8.39(s,2H),7.71(s,2H),7.65(s,2H),4.61(brs,2H),4.39(b rs,2H),3.82(s,6H),3.25(t,J=6.3Hz,4H),2.59(t,J=6.4Hz,4H),2.28–2.26(m,1H),1.23(s,3H)ppm. 13 C NMR (75MHz, DMSO-d6): δ=193.66,173.82,150.74,147.66,144.90,137.52,13 5.12,134.08,111.44,108.44,67.12,56.09,43.12,32.66,28.12,25.23ppm. HRMS(ESI – ): Calculated value C 30 H 29 O 10 Se2 - ,(MH) - ,709.0097; measured value 709.0096.

[0317] Example 35 Preparation of 4,4'-(((cyclopropane-1,1-diyl)bis(methylene))bis(oxy))bis(6-methoxybenzo[b]selenophene-5,2-diyl))bis(4-oxobutanoic acid) (C34)

[0318]

[0319] Referring to the preparation methods described in Examples 1 and 2, two molecules of intermediate 15a were connected via 1,1-bis(bromomethyl)cyclopropane to prepare compound C34. 1 H NMR (300MHz, DMSO-d6): δ = 12.24 (s, 2H), 8.30 (s, 2H), 7.68 (s, 2H), 7.53 (s, 2H), 4.0 4(s,4H),3.82(s,6H),3.25(t,J=6.2Hz,4H),2.60(t,J=6.1Hz,4H),0.75(s,4H)ppm. 13 C NMR (75MHz, DMSO-d6): δ=193.63,173.84,150.67,147.82,144.73,137.02,13 5.09,134.10,110.71,108.21,72.01,55.98,38.76,32.63,28.11,15.48ppm. HRMS(ESI – ): Calculated value C 31 H 29 O 10 Se2 - ,(MH) - ,721.0097; measured value 721.0096.

[0320] Example 36 Preparation of 4,4'-(((2,2-dimethylpropane-1,3-diyl)bis(oxy))bis(6-methoxybenzo[b]selenophene-5,2-diyl))bis(4-oxobutanoic acid) (C35)

[0321]

[0322] Referring to the preparation method described in Examples 1 and 2, two molecules of intermediate 15a were connected via 1,3-dibromo-2,2-dimethylpropane to prepare compound C35. 1 H NMR (300MHz, DMSO-d6): δ = 12.23 (s, 2H), 8.40 (s, 2H), 7.71 (s, 2H), 7.52 (s, 2H), 3.9 7(s,4H),3.83(s,6H),3.17(t,J=6.1Hz,4H),2.58(t,J=6.1Hz,4H),1.10(s,6H)ppm. 13C NMR (75MHz, DMSO-d6): δ=194.18,173.65,149.96,147.52,143.25,137.05,13 5.11,134.41,110.29,108.19,75.34,56.27,38.62,37.39,29.55,23.22ppm. HRMS(ESI – ): Calculated value C 31 H 31 O 10 Se2 - ,(MH) - ,723.0253; measured value 723.0250.

[0323] Example 37 Preparation of 4,4'-((butane-1,3-diylbis(oxy))bis(6-methoxybenzo[b]selenophene-5,2-diyl))bis(4-oxobutanoic acid) (C36)

[0324]

[0325] Referring to the preparation method described in Examples 1 and 2, two molecules of intermediate 15a were connected via 1,3-dibromobutane to prepare compound C36. 1 H NMR (300MHz, DMSO-d6): δ=12.21(s,2H),8.42(s,2H),7.71(s,1H),7.69(s,1H),7.52(s,2H),4.48-4.36(m,1H),4.14 -3.98(m,2H),3.83(s,6H),3.12(t,J=6.0Hz,4H),2.61(t,J=6.1Hz,4H),2.14-1.99(m,2H),1.47(d,J=6.9Hz,3H)ppm. 13 C NMR (75MHz, DMSO-d6): δ=194.56,173.03,149.12,147.89,143.46,137.28,135.1 2,134.99,110.74,108.89,75.79,67.85,56.81,37.95,35.86,29.57,20.26ppm. HRMS(ESI – ): Calculated value C 30 H 29 O 10 Se2 - ,(MH) - ,709.0097; measured value 709.0099.

[0326] Example 38 Preparation of 4,4'-(((2-oxopropane-1,3-diyl)bis(oxy))bis(6-methoxybenzo[b]selenophene-5,2-diyl))bis(4-oxobutanoic acid) (C37)

[0327]

[0328] Referring to the preparation method described in Examples 1 and 2, two molecules of intermediate 15a were connected via 1,3-dibromoacetone to prepare compound C37. 1 H NMR (300MHz, DMSO-d6): δ = 12.25 (s, 2H), 8.37 (s, 2H), 7.73 (s, 2H), 7.55 (s, 2H) ), 4.98 (s, 4H), 3.83 (s, 6H), 3.15 (t, J = 5.9Hz, 4H), 2.60 (t, J = 6.0Hz, 4H) ppm. 13 C NMR (75MHz, DMSO-d6): δ=200.14,194.03,173.48,149.20,147.30,143.86 ,137.33,135.35,133.48,109.92,108.46,71.09,56.86,37.37,29.19ppm. HRMS(ESI – ): Calculated value C 29 H 25 O 11 Se2 - ,(MH) - ,708.9733; measured value 708.9730.

[0329] Example 39 Preparation of 4,4'-(((2-hydroxypropane-1,3-diyl)bis(oxy))bis(6-methoxybenzo[b]selenophene-5,2-diyl))bis(4-oxobutanoic acid) (C38)

[0330]

[0331] 100 mg of compound C37 (0.14 mmol), 6 mL of tetrahydrofuran and 3 mL of water were added to a 100 mL reaction bottle, and 21 mg of sodium borohydride (0.56 mmol) was added four times. The reaction mixture was stirred at room temperature for 30 min. TLC (dichloromethane: methanol = 10: 1, v / v) detected that the raw material reaction was complete, 40 mL of 2N HCl was added, and 15 mL of ethyl acetate was used for extraction three times. The organic phases were combined, washed with water, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography (dichloromethane: methanol = 30: 1, v / v) to obtain 89 mg of compound C38 as a light yellow solid with a yield of 89%.1 H NMR (300MHz, DMSO-d6): δ=12.24(s,2H),8.41(s,2H),7.68(s,2H),7.52(s,2H),4.72(s ,1H),4.16-4.09(m,5H),3.84(s,6H),3.09(t,J=6.0Hz,4H),2.59(t,J=5.8Hz,4H)ppm. 13 C NMR (75MHz, DMSO-d6): δ=194.94,173.71,149.61,147.54,143.03,137.22,135.31,133.82,109.67,108.06,71.45,69.07,56.59,37.08,29.41ppm. HRMS(ESI – ): Calculated value C 29 H 27 O 11 Se2 - ,(MH) - ,710.9889; measured value 710.9892.

[0332] Example 40 Preparation of 4,4'-((propane-1,3-diylbis(oxy))bis(benzo[b]selenophene-5,2-diyl))bis(4-oxobutanoic acid) (C39)

[0333]

[0334] Referring to the preparation method described in Examples 1 and 2, two molecules of intermediate 15k were connected via 1,3-dibromopropane to prepare compound C39. 1 H NMR (300MHz, DMSO-d6): δ = 12.19 (s, 2H), 8.39 (s, 2H), 7.70 (s, 2H), 7.53 (d, J = 7.4Hz, 2H), 7.34 (dd, J1 = 7.2Hz, J2=3.6Hz,2H),4.22(t,J=5.8Hz,4H),3.15(t,J=6.0Hz,4H),2.59(t,J=5.9Hz,4H),2.30(t,J=6.0Hz,2H)ppm. 13 C NMR (75MHz, DMSO-d6): δ=194.09,173.99,147.72,143.81,137.83,135.27,133.16,109.91,108.73,107.05,68.68,37.17,29.82,29.40ppm. HRMS(ESI – ): Calculated value C 27 H23 O8Se2 - ,(MH) - ,634.9729; measured value 634.9730.

[0335] Example 41 Preparation of 4,4'-((propane-1,3-diylbis(oxy))bis(6-methylbenzo[b]selenophene-5,2-diyl))bis(4-oxobutanoic acid) (C40)

[0336]

[0337] Referring to the preparation methods described in Examples 1 and 2, two molecules of intermediate 151 were connected via 1,3-dibromopropane to prepare compound C40.

[0338] 1 H NMR (300MHz, DMSO-d6): δ=12.17(s,2H),8.41(s,2H),7.70(s,2H),7.53(s,2H),4.17(t,J=5. 8Hz, 4H), 3.15 (t, J = 6.2Hz, 4H), 2.62 (t, J = 6.2Hz, 4H), 2.28 (t, J = 6.1Hz, 2H), 2.12 (s, 6H) ppm. 13 C NMR (75MHz, DMSO-d6): δ=195.04,172.50,147.63,144.87,137.49,135.16,133.01,130.67,109.79,107.67,67.47,37.56,30.31,29.69,16.59ppm. HRMS(ESI – ): Calculated value C 29 H 27 O8Se2 - ,(MH) - ,663.0042; measured value 663.0046.

[0339] Example 42 Preparation of 4,4'-((propane-1,3-diylbis(oxy))bis(6-(difluoromethoxy)benzo[b]selenophene-5,2-diyl))bis(4-oxobutanoic acid) (C41)

[0340]

[0341] Referring to the preparation method described in Examples 1 and 2, two molecules of intermediate 15m were connected via 1,3-dibromopropane to prepare compound C41. 1H NMR (300MHz, DMSO-d6): δ = 12.24 (s, 2H), 8.40 (s, 2H), 7.69 (s, 2H), 7.52 (s, 2H), 6.65 (t, J = 68.2Hz, 2H), 4.23 (t, J = 6.4Hz, 4H), 3.17 (t, J = 6.1Hz, 4H), 2.60 (t, J = 6.0Hz, 4H), 2.31 (t, J = 6.1Hz, 2H) ppm. 13 C NMR (75MHz, DMSO-d6): δ=194.80,172.76,168.31,147.12,144.35,137.53 ,135.48,133.22,128.89,110.26,108.48,67.23,37.98,30.07,29.56ppm. HRMS(ESI – ): Calculated value C 29 H 23 F4O 10 Se2 - ,(MH) - ,766.9563; measured value 766.9561.

[0342] Example 43 Preparation of 4,4'-(butane-1,4-diylbis(6-methoxybenzo[b]selenophene-5,2-diyl))bis(4-oxobutanoic acid) (C42)

[0343]

[0344] Step 1: Preparation of ethyl 4-(5-(4-((tert-butyldimethylsilyl)oxy)butyl)-6-methoxybenzo[b]selenophene-2-yl)-4-oxobutanoate (38)

[0345] 128 mg I2 (0.5 mmol), 0.98 g zinc powder (15.0 mmol) and 10 mL anhydrous tetrahydrofuran were added to a dry 50 mL reaction bottle, and the air in the bottle was replaced with N2 three times. The resulting mixture was reacted at room temperature until the red color of iodine faded. 2.68 g (4-bromobutoxy) tert-butyldimethylsilane (10.0 mmol) was added, and the reaction solution was stirred for 3 h under heating at 80 ° C. After the reaction solution was cooled to room temperature, a tetrahydrofuran solution of compound (4-((tert-butyldimethylsilyl)oxy)butyl) zinc bromide (compound 37) was obtained, and it was immediately used directly in the next step reaction.

[0346] 2.09 g of compound 15n (5.0 mmol), 0.20 g of C-Phos Pd G3 ([(2-dicyclohexylphosphino-2',6'-bis(N,N-dimethylamino)-1,1'-biphenyl)-2-(2'-amino-1,1'-biphenyl)]methanesulfonate palladium (II), 0.25 mmol) and 20 mL of anhydrous tetrahydrofuran were added to a 100 mL reaction bottle, and the air in the bottle was replaced by N2 three times. A freshly prepared tetrahydrofuran solution of (4-((tert-butyldimethylsilyl)oxy)butyl)zinc bromide (compound 37) (1 M, 10 mL, 10 mmol) was slowly added with a syringe. The resulting reaction mixture was stirred at room temperature for 18 h. After the reaction was complete, 100 mL of water was added and the mixture was extracted three times with 20 mL of ethyl acetate by TLC detection (petroleum ether:ethyl acetate=4:1, v / v). The organic phases were combined, washed with water, washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 10: 1, v / v) to obtain 1.24 g of compound 38 as a yellow solid with a yield of 47%.

[0347] 1 H NMR (300MHz, CDCl3): δ = 8.05 (s, 1H), 7.96 (s, 1H), 7.30 (s, 1H), 4.22 (q, J = 7.2Hz, 2H), 3.96 (s, 3H), 3.68 (t, J = 7.0Hz, 2H), 3.17 (t, J=6.9Hz,2H),2.67(t,J=6.8Hz,2H),2.59(t,J=6.9Hz,2H),1.72-1.55(m,4H),1.27(t,J=7.4Hz,3H),0.84(s,9H),0.02(s,6H)ppm. HRMS(ESI + ): Calculated value C 25 H 39 O5S + ,(M+H) + ,527.1726; measured value 527.1730.

[0348] Step 2: Preparation of ethyl 4-(5-(4-hydroxybutyl)-6-methoxybenzo[b]selenophene-2-yl)-4-oxobutanoate (39)

[0349] 1.24 g of compound 38 (2.35 mmol) and 5 mL of methanol were added to a 50 mL reaction bottle, and 5 mL of water and 5 mL of acetic acid were added. The resulting reaction mixture was stirred at room temperature for 18 h. After the reaction of the raw materials was complete, 40 mL of water was added and extracted three times with 15 mL of ethyl acetate according to TLC detection (petroleum ether: ethyl acetate = 4:1, v / v). The organic phases were combined, washed with water, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 8:1, v / v) to obtain 0.88 g of compound 39 as a yellow solid with a yield of 91%.

[0350] 1 H NMR (300MHz, CDCl3): δ = 8.07 (s, 1H), 7.96 (s, 1H), 7.31 (s, 1H), 4.20 (q, J = 7.0Hz, 2H), 4.06 (t, J = 6.8Hz, 2H), 3.97 (s, 3H), 3.21 (t, J = 6.9Hz, 2H), 2.72-2.62 (m, 4H), 1.75-1.66 (m, 4H), 1.25 (t, J = 7.0Hz, 3H) ppm. HRMS(ESI + ): Calculated value C 19 H 25 5S + ,(M+H) + ,413.0862; measured value 413.0864.

[0351] Step 3: Preparation of ethyl 4-(5-(4-bromobutyl)-6-methoxybenzo[b]selenophene-2-yl)-4-oxobutanoate (40)

[0352] 0.88g of compound 39 (2.14mmol), 1.12g of triphenylphosphine (4.28mmol) and 10mL of tetrahydrofuran were added to a 50mL reaction bottle and placed in an ice bath for cooling. 0.57g of NBS (N-bromosuccinimide, 3.21mmol) was added at 0℃. After the addition was complete, stirring was continued at 0℃ for 1h. After TLC detection (petroleum ether: ethyl acetate = 1:1, v / v) the raw materials reacted completely, 50mL of water was added and extracted three times with 15mL of ethyl acetate. The organic phases were combined, washed with water, washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 10:1, v / v) to obtain 0.86g of compound 40 as a yellow solid with a yield of 85%.

[0353] 1H NMR (300MHz, CDCl3): δ=8.05(s,1H),7.95(s,1H),7.26(s,1H),4.17(q,J=7.0Hz,2H),3.97(s,3H),3.48(t,J=7.5 Hz,2H),3.21(t,J=6.9Hz,2H),2.70-2.63(m,4H),1.96-1.86(m,2H),1.82-1.77(m,2H),1.25(t,J=7.2Hz,3H)ppm. HRMS(ESI + ): Calculated value C 19 H 24 BrO4Se + ,(M+H) + ,475.0018; measured value 475.0017.

[0354] Step 4: Preparation of ethyl 4-(6-methoxy-5-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butyl)benzo[b]selenophene-2-yl)-4-oxobutanoate (42)

[0355] 0.86g of compound 40 (1.82mmol), 0.69g of biboric acid pinacol ester (2.73mmol), 35mg of cuprous iodide (0.18mmol), 62mg of triphenylphosphine (0.24mmol), 0.29g of lithium tert-butoxide (3.64mmol) and 8mL of DMF were added to a 50mL reaction bottle, and the air in the bottle was replaced by N2 five times. The resulting reaction mixture was stirred at room temperature for 18h. After the reaction of the raw materials was complete, 40mL of ethyl acetate was added to dilute the reaction solution, filtered through diatomaceous earth, and the filtrate was concentrated. The residue was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 10: 1, v / v) to obtain 0.69g of compound 42 as a yellow solid with a yield of 73%.

[0356] 1 H NMR (300MHz, CDCl3): δ = 8.07 (s, 1H), 7.95 (s, 1H), 7.24 (s, 1H), 4.21 (q, J = 7.3Hz, 2H), 3.96 (s, 3H), 3.19 (t, J = 6.9Hz, 2H), 2. 70(t,J=6.7Hz,2H),2.61(t,J=7.1Hz,2H),1.67-1.56(m,4H),1.39(t,J=5.6Hz,2H)1.22(t,J=7.5Hz,3H),1.21(s,12H)ppm. HRMS(ESI + ): Calculated value C 25 H36 BO6Se + ,(M+H) + ,523.1765; measured value 523.1766.

[0357] Step 5: Preparation of 4,4'-(butane-1,4-diylbis(6-methoxybenzo[b]selenophene-5,2-diyl))bis(4-oxobutyric acid diethyl ester) (43)

[0358] 100 mg of compound 42 (0.19 mmol), 119 mg of compound 15n (0.29 mmol), 31 mg of PdCl2(dppf)-CH2Cl2 (1,1-bis(diphenylphosphino)ferrocenepalladium dichloride dichloromethane complex, 0.038 mmol), 248 mg of cesium carbonate (0.76 mmol), 4 mL of 1,4-dioxane and 1 mL of water were added to a 50 mL reaction bottle, and the resulting mixture was reacted at 100°C for 18 h. TLC detection (petroleum ether:ethyl acetate=2:1, v / v) showed that the raw materials reacted completely. After the reaction solution was cooled to room temperature, it was filtered and the filtrate was concentrated. The resulting residue was purified by silica gel column chromatography (petroleum ether:ethyl acetate=6:1, v / v) to obtain 389 mg of compound 4 as a yellow solid with a yield of 64%.

[0359] 1 H NMR (300MHz, CDCl3): δ = 8.07 (s, 2H), 7.97 (s, 2H), 7.28 (s, 2H), 4.20 (q, J = 7.6Hz, 4H), 3.96 (s, 6H), 3.20 (t,J=6.3Hz,4H),2.78-2.70(m,4H),2.63(t,J=5.6Hz,4H),1.76-1.69(m,4H),1.20(t,J=7.2Hz,6H)ppm. HRMS(ESI + ): Calculated value C 34 H 39 O8Se2 + ,(M+H) + ,735.0970; measured value 735.0967.

[0360] Step 6: Preparation of 4,4'-(butane-1,4-diylbis(6-methoxybenzo[b]selenophene-5,2-diyl))bis(4-oxobutanoic acid) (C42)

[0361] 89 mg of compound 43 (0.12 mmol), 1 mL of methanol and 1 mL of tetrahydrofuran were added to a 25 mL reaction bottle, and 400 μL of 2N NaOH aqueous solution was added. The resulting reaction mixture was stirred at 55°C for 1 h. After the reaction of the raw materials was complete, the reaction solution was concentrated, and the residue was adjusted to pH 2-3 with 1N HCl, and then extracted three times with 10 mL of ethyl acetate. The organic phases were combined, washed with water, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography (dichloromethane: methanol = 30: 1, v / v) to obtain 59 mg of compound C42 as a light yellow solid with a yield of 73%.

[0362] 1 H NMR (300MHz, DMSO-d6): δ=12.24(s,2H),8.41(s,2H),8.37(s,2H),7.56(s,2H),3.86(s,6 H), 3.15 (t, J = 6.3Hz, 4H), 2.71-2.67 (m, 4H), 2.60 (t, J = 6.1Hz, 4H), 1.71-1.66 (m, 4H) ppm. 13 C NMR (75MHz, DMSO-d6): δ=194.20,173.11,149.49,143.05,137.39,135.45,133.94,111.93,109.13,108.41,56.47,37.18,30.21,29.99,29.72ppm. HRMS(ESI – ): Calculated value C 30 H 29 O8Se2 - ,(MH) - ,677.0198; measured value 677.0195.

[0363] Example 44 Preparation of 4,4'-(propane-1,3-diylbis(6-methoxybenzo[b]selenophene-5,2-diyl))bis(4-oxobutanoic acid) (C43)

[0364]

[0365] Referring to the preparation method described in Example 43, (4-bromobutoxy)tert-butyldimethylsilane was replaced with (3-bromopropoxy)tert-butyldimethylsilane, and compound C43 was prepared by the same synthetic method.

[0366] 1H NMR (300MHz, DMSO-d6): δ=12.24(s,2H),8.40(s,2H),8.37(s,2H),7.53(s,2H),3.85(s,6H), 3.20(t,J=5.9Hz,4H), 2.71(t,J=7.0Hz,4H), 2.61(t,J=6.1Hz,4H), 2.30(t,J=5.8Hz,2H)ppm. 13 C NMR (75MHz, DMSO-d6): δ=194.02,173.64,149.55,143.94,137.06,135.60,133.12,112.83,109.94,107.14,56.86,37.83,29.61,29.39,28.33ppm. HRMS(ESI – ): Calculated value C 29 H 27 O8Se2 - ,(MH) - ,663.0042; measured value 663.0038.

[0367] Example 45 Preparation of 4,4'-(pentane-1,5-diylbis(6-methoxybenzo[b]selenophene-5,2-diyl))bis(4-oxobutanoic acid) (C44)

[0368]

[0369] Referring to the preparation method described in Example 43, (4-bromobutoxy)tert-butyldimethylsilane was replaced with (5-bromopentyloxy)tert-butyldimethylsilane as the reactant, and compound C44 was prepared by the same synthetic method. 1 H NMR (300MHz, DMSO-d6): δ = 12.23 (s, 2H), 8.43 (s, 2H), 8.36 (s, 2H), 7.52 (s, 2H), 3.86 (s, 6H), 3.17 (t, J=5.9Hz,4H),2.68(t,J=7.1Hz,4H),2.61(t,J=6.0Hz,4H),1.69-1.60(m,4H),1.45-1.36(m,2H)ppm. 13 C NMR (75MHz, DMSO-d6): δ=193.74,173.12,149.89,143.22,137.28,134.14,13 3.33,111.50,110.06,108.09,56.91,37.62,30.95,29.80,29.03,28.17ppm. HRMS(ESI – ): Calculated value C31 H 31 O8Se2 - ,(MH) - ,691.0355; measured value 691.0353.

[0370] Example 46 Preparation of 4-(5-(4-(2-(4-ethoxy-4-oxobutanoyl)-6-methoxybenzo[b]selenophene-5-yl)butoxy)-6-methoxybenzo[b]selenophene-2-yl)-4-oxobutanoic acid (C45)

[0371]

[0372] Step 1: Preparation of ethyl 4-(5-(4-(2-(4-ethoxy-4-oxobutanoyl)-6-methoxybenzo[b]selenophene-5-yl)butoxy)-6-methoxybenzo[b]selenophene-2-yl)-4-oxobutanoate (44)

[0373] 100 mg of compound 15n (0.28 mmol), 89 mg of compound 40 (0.19 mmol), 116 mg of K2CO3 (0.84 mmol), 5 mg of KI (0.028 mmol), 7 mg of 18-crown ether-6 (0.028 mmol) and 4 mL of DMF were added to a 25 mL reaction bottle, and the resulting reaction solution was stirred at 50 ° C for 8 h. After the reaction of the raw materials was complete, 20 mL of water was added and extracted three times with 8 mL of ethyl acetate. The organic phases were combined, washed with water, washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 2: 1, v / v) to obtain 115 mg of compound 44 as a yellow solid with a yield of 81%.

[0374] 1 H NMR (300MHz, CDCl3): δ=8.07(s,1H),8.05(s,1H),7.97(s,1H),7.34(s,1H),7.28(s,1H),7.26(s,1H),4.11-4.03(m,2H),3.96(s, 3H), 3.94 (s, 3H), 3.15 (t, J = 6.1Hz, 4H), 2.73 (t, J = 6.5Hz, 2H), 2.58 (t, J = 5.8Hz, 4H), 1.83-1.71 (m, 4H), 1.20 (t, J = 7.3Hz, 6H) ppm. HRMS(ESI + ): Calculated value C 34 H 39 O9Se2 + ,(M+H)+ ,751.0919; measured value 751.0920.

[0375] Step 2: Preparation of 4-(5-(4-(2-(4-ethoxy-4-oxobutanoyl)-6-methoxybenzo[b]selenophene-5-yl)butoxy)-6-methoxybenzo[b]selenophene-2-yl)-4-oxobutanoic acid (C45)

[0376] 115 mg of compound 44 (0.15 mmol), 1.5 mL of methanol and 1.5 mL of tetrahydrofuran were added to a 25 mL reaction bottle, and 500 μL of 2N NaOH aqueous solution was added. The resulting reaction mixture was stirred at 55°C for 1 h. After the reaction of the raw materials was complete, the reaction solution was concentrated, and the resulting residue was adjusted to pH 2-3 with 1N HCl and extracted three times with 10 mL of ethyl acetate. The organic phases were combined, washed with water, washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography (dichloromethane: methanol = 30: 1, v / v) to obtain 69 mg of compound C45 as a light yellow solid with a yield of 66%. 1 H NMR (300MHz, DMSO-d6): δ=12.25(s,2H),8.43(s,1H),8.40(s,1H),8.38(s,1H),7.71(s,1H),7.62(s,1H),7.60(s,1H),4.10(t,J =5.5Hz,2H),3.84(s,3H),3.83(s,3H),3.18(t,J=5.9Hz,4H),2.72(t,J=7.0Hz,2H),2.59(t,J=6.0Hz,4H),1.82-1.70(m,4H)ppm. 13 C NMR (75MHz, DMSO-d6): δ=194.75,176.84,158.91,149.17,147.52,141.56,138.71,138.24,133.14,131.79,1 31.22,126.55,126.16,112.25,110.07,108.09,69.22,56.16,55.70,37.89,30.08,29.46,29.07,26.20ppm. HRMS(ESI – ): Calculated value C 30 H 29 O9Se2 - ,(MH) - ,693.0147; measured value 693.0144.

[0377] Example 47 Preparation of 4-(5-(4-((2-(3-carboxypropanoyl)-6-methoxybenzo[b]selenophene-5-yl)amino)butyl)-6-methoxybenzo[b]selenophene-2-yl)-4-oxobutanoic acid (C46)

[0378]

[0379] Referring to the preparation method described in Example 46, Compound 15o was used instead of Compound 15n as the reactant, and Compound C46 was prepared by the same synthetic method. 1 H NMR (300MHz, DMSO-d6): δ=12.25(s,2H),8.44(s,1H),8.42(s,1H),8.39(s,1H),7.73(s,1H),7.61(s,1H),7.60(s,1H),6.98(t,J=8.3Hz,1 H),3.84(s,3H),3.83(s,3H),3.34-3.27(m,2H),3.17(t,J=6.2Hz,4H),2.70(t,J=7.0Hz,2H),2.60(t,J=6.0Hz,4H),1.68-1.61(m,4H)ppm. 13 C NMR (75MHz, DMSO-d6): δ=194.80,176.60,158.89,149.36,147.59,141.35,138.31,138.11,133.17,131.81,1 31.16,126.56,126.36,112.76,110.92,108.35,56.14,55.47,43.76,37.61,30.53,29.75,29.69,26.37ppm. HRMS(ESI – ): Calculated value C 30 H 30 NO8Se2 - ,(MH) - ,692.0307; measured value 692.0309.

[0380] Example 48 Preparation of 4-(5-(3-((2-(3-carboxypropanoyl)-6-methoxybenzo[b]selenophene-5-yl)amino)propoxy)-6-methoxybenzo[b]selenophene-2-yl)-4-oxobutanoic acid (C47)

[0381]

[0382] Referring to the preparation methods described in Examples 1 and 2, one molecule of intermediate 15a and one molecule of intermediate 15o were connected via 1,3-dibromopropane to prepare compound C47.

[0383] 1 H NMR (300MHz, DMSO-d6): δ=12.21(s,2H),8.43(s,1H),8.42(s,1H),7.69(s,1H),7.67(s,1H),7.62(s,1H),7.60(s,1H),6.95(t,J=8.0Hz,1 H),4.11(t,J=5.7Hz,2H),3.85(s,3H),3.83(s,3H),3.39-3.25(m,2H),3.19(t,J=6.1Hz,4H),2.58(t,J=6.0Hz,4H),2.05-2.00(m,2H)ppm. 13 C NMR (75MHz, DMSO-d6): δ=194.97,176.32,158.88,149.79,147.80,141.92,138.64,138.35,133.13,131.2 9,131.07,127.27,126.91,112.63,110.21,108.48,67.58,56.05,55.22,43.34,37.89,29.70,28.74ppm. HRMS(ESI – ): Calculated value C 29 H 28 NO9Se2 - ,(MH) - ,694.0100; measured value 694.0098.

[0384] Example 49 Preparation of 4,4'-((propane-1,3-diylbis(oxy))bis(6-methoxybenzo[b]selenophene-5,2-diyl))bis(4-oxobutyric acid-1,1,1-trifluoro-2-propanol ester) (C49)

[0385]

[0386] 100 mg of compound C1 (0.14 mmol), 66 mg of 1,1,1-trifluoro-2-propanol (0.58 mmol), 89 mg of DCC (N,N'-dicyclohexylcarbodiimide, 0.43 mmol), 3.5 mg of DMAP (4-dimethylaminopyridine, 0.029 mmol) and 3 mL of dichloromethane were added to a 25 mL reaction bottle, and the resulting mixture was stirred at room temperature for 8 h. After TLC detection (dichloromethane: methanol = 10: 1, v / v), the raw materials were completely reacted, and 9 mL of dichloromethane was added for dilution, filtered, and the filtrate was concentrated. 6 mL of ethyl acetate was added to the resulting residue and placed in an ice bath for 10 min, filtered, and the filtrate was concentrated and purified by silica gel column chromatography (petroleum ether: ethyl acetate = 2: 1, v / v) to obtain 80 mg of compound C49 as a light yellow solid with a yield of 63%.

[0387] 1 H NMR (300MHz, DMSO-d6): δ = 8.43 (s, 2H), 7.69 (s, 2H), 7.56 (s, 2H), 5.16-5.05 (m, 2H), 4.32-4.14 (m, 4 H),3.85(s,6H),3.14-3.06(m,4H),2.62-2.52(m,4H),2.38–2.16(m,2H),1.40(d,J=7.8Hz,6H)ppm. 13 C NMR (75MHz, DMSO-d6): δ=194.36,171.25,150.23,147.46,145.84,137.02,135.0 3,134.21,110.80,108.28,70.53,67.46,56.57,37.50,30.35,30.12,16.99ppm. HRMS(ESI + ): Calculated value C 35 H 35 F6O 10 Se2 + ,(M+H) + ,889.0459; measured value 889.0462.

[0388] Example 50 Preparation of 4,4'-((propane-1,3-diylbis(oxy))bis(6-methoxybenzo[b]selenophene-5,2-diyl))bis(4-oxobutyramide) (C50)

[0389]

[0390] 100 mg of compound C1 (0.14 mmol), 44 mg of N-methylmorpholine (0.43 mmol) and 3 mL of tetrahydrofuran were added to a 25 mL reaction bottle, and 59 mg of isobutyl chloroformate (0.43 mmol) was added dropwise under an ice bath. After the addition was complete, the mixture was transferred to room temperature and stirred for 1 h. 0.1 mL of ammonia water was added dropwise under an ice bath again, and the resulting reaction solution was stirred at room temperature for 4 h. After the reaction of the raw materials was complete, 15 mL of water was added and the mixture was extracted three times with 10 mL of ethyl acetate. The organic phases were combined, washed with water, washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated, and the resulting residue was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 1:1, v / v) to obtain 74 mg of compound C50 as a yellow solid with a yield of 74%. 1 H NMR (300MHz, DMSO-d6): δ = 8.42 (s, 2H), 7.70 (s, 2H), 7.56 (s, 2H), 4.22 (t, J = 5.8Hz, 4 H),3.84(s,6H),3.13(t,J=6.1Hz,4H),2.42(t,J=6.3Hz,4H),2.32–2.22(m,2H)ppm. 13 C NMR (75MHz, DMSO-d6): δ=194.90,175.41,150.35,147.10,145.47,137.64,135.91,134.35,109.92,108.75,67.36,56.81,37.66,33.98,30.13ppm. HRMS(ESI + ): Calculated value C 29 H 31 N2O8Se2 + ,(M+H) + ,695.0405; measured value 695.0405.

[0391] Example 51 Preparation of 4,4'-((propane-1,3-diylbis(oxy))bis(6-methoxybenzo[b]selenophene-5,2-diyl))bis(N-hydroxy-4-oxobutyramide) (C51)

[0392]

[0393] 100 mg of compound C1 (0.14 mmol), 164 mg of HATU (O-(7-azabenzotriazole-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate, 0.43 mmol), 130 mg of N,N-diisopropylethylamine (1.01 mmol) and 3 mL of DMF were added to a 25 mL reaction bottle, and the resulting mixture was stirred at room temperature for 30 min. Subsequently, 40 mg of hydroxylamine hydrochloride (0.58 mmol) was added, and stirring was continued at room temperature for 4 h. After the reaction of the raw materials was complete by TLC detection (dichloromethane: methanol = 10: 1, v / v), 15 mL of water was added to the reaction solution, and the mixture was extracted three times with 10 mL of ethyl acetate. The organic phases were combined, washed with water, washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 1: 1, v / v) to obtain 149 mg of compound C5 as a light yellow solid with a yield of 47%.

[0394] 1 H NMR (300MHz, DMSO-d6): δ = 8.45 (s, 2H), 7.70 (s, 2H), 7.57 (s, 2H), 4.22 (t, J = 5.9Hz, 4 H), 3.83 (s, 6H), 3.10 (t, J = 6.0Hz, 4H), 2.38 (t, J = 6.2Hz, 4H), 2.31–2.22 (m, 2H) ppm. 13 C NMR (75MHz, DMSO-d6): δ=195.18,172.93,150.44,147.97,145.86,137.00,135.01,134.96,109.65,108.64,67.51,56.28,37.79,30.86,30.03ppm. HRMS(ESI + ): Calculated value C 29 H 31 N2O 10 Se2 + ,(M+H) + ,727.0304; measured value 727.0308.

[0395] Example 52 Preparation of 4,4'-((propane-1,3-diylbis(oxy))bis(6-methoxybenzo[b]selenophene-5,2-diyl))bis(N-methoxy-4-oxobutanamide) (C52)

[0396]

[0397] Referring to the preparation method described in Example 51, the raw material hydroxylamine hydrochloride was replaced with methoxylamine hydrochloride, and compound C52 was prepared by the same synthetic method. 1H NMR (300MHz, DMSO-d6): δ = 11.08 (s, 2H), 8.47 (s, 2H), 7.71 (s, 2H), 7.55 (s, 2H), 4.23 (t, J = 5.9Hz, 4H), 3.82 (s, 6H), 3.57 (s, 6H), 3.11 (t, J = 6.0Hz, 4H), 2.35 (t, J = 6.2Hz, 4H), 2.33–2.24 (m, 2H)ppm. 13 C NMR (75MHz, DMSO-d6): δ=197.20,174.68,152.02,147.66,144.79,138.69,13 6.91,133.50,109.43,107.28,67.77,56.21,59.34,38.07,31.72,28.54ppm. HRMS(ESI + ): Calculated value C 31 H 35 N2O 10 Se2 + ,(M+H) + ,755.0617; measured value 755.0622.

[0398] Example 53 Preparation of 4,4'-((propane-1,3-diylbis(oxy))bis(6-methoxybenzo[b]selenophene-5,2-diyl))bis(1-((isopropylamino)oxy)butane-1,4-dione) (C53)

[0399]

[0400] Referring to the preparation method described in Example 51, the raw material hydroxylamine hydrochloride was replaced with N-isopropylhydroxylamine hydrochloride, and compound C53 was prepared by the same synthesis method. 1 H NMR (300MHz, DMSO-d6): δ = 8.41 (s, 2H), 7.71 (s, 2H), 7.59 (s, 2H), 4.22 (t, J = 6.1Hz, 4H), 3.85 (s, 6H), 3 .15(m,2H),3.09(t,J=6.3Hz,4H),2.45(t,J=6.1Hz,4H),2.30–2.23(m,2H),0.99(d,J=6.3Hz,12H)ppm.

[0401] 13C NMR (75MHz, DMSO-d6): δ=199.07,173.56,150.17,148.82,138.71,137.65,134.53,132.18,111.30,108.69,67.34,56.18,51.99,37.26,30.30ppm. HRMS(ESI + ): Calculated value C 35 H 43 N2O 10 Se2 + ,(M+H) + ,811.1243; measured value 811.1248.

[0402] Example 54 Based on THP1-Lucia, RAW-Lucia luciferase reporter gene experiment

[0403] THP1-dual TM (Invivogen:thpd-nfis) cells or RAW-Lucia TM (Invivogen:rawl-isg) cells were diluted with culture medium and 180 μL of cell suspension was inoculated into a 96-well plate, so that each well contained 1×10 5 cells. Then, 20 μL of the compound to be tested was added to a 96-well plate (the final concentration of the compound was 10 μM and the final volume of each well was 200 μL) and incubated at 37°C for 24 hours. Then, 10 μL of the supernatant was aspirated into a new 96-well white plate, and 50 μL of QUANT-Luc reagent (Invivogene: rep-qlc1, rep-qlc2) was added. After thorough mixing, the assay was immediately performed using an ELISA instrument. The experiment was set up with 3 replicate wells. The blank well was cell culture medium, and dimethyl sulfoxide (DMSO) was added to the negative well. The test results were expressed as folds, which were calculated by (test well-blank well) / (negative well-blank well).

[0404] The test results are shown in Table 4 below, with 2',3'-cGAMP as the positive control. 2',3'-cGAMP is the endogenous ligand of STING protein and is a recognized high-activity STING agonist. *** indicates an excitation multiple of more than 20 times, ** indicates an excitation multiple of 10 to 20 times, and * indicates an excitation multiple of 1 to 10 times.

[0405] Table 4 Luciferase reporter gene assay agonist activity of the compounds of the present invention

[0406]

[0407]

[0408] After the compound acts on the cells, the multiple of luciferase expression caused by the negative control can reflect the compound's ability to activate the cGAS-STING pathway. As can be seen from Table 4, the relative activation multiple of the compound in activating the cGAS-STING pathway in the luciferase reporter gene experiment is 1 to 20 times or more, so it has good cGAS-STING pathway activating activity, which can provide a basis for the preparation of drugs that activate the cGAS-STING pathway.

[0409] Example 55 Interferon β induction experiment based on THP1 cells

[0410] The secretion of cytokine IFNβ was determined by enzyme-linked immunosorbent assay (ELISA). THP1 cells were seeded in 96-well plates (RPMI 1640 medium without serum) so that the number of cells per well was 5-7×10 5 The test compound was prepared into a 10mM DMSO stock solution, diluted with culture medium to the target concentration and added to a 96-well plate containing cells (the final concentration of the compound was 20μM, and the final volume of each well was 200μL), and incubated at 37°C, 5% CO2 for 3.5h. The cells were then collected and centrifuged at 4°C, 1000rpm for 20 minutes, and the supernatant was collected for ELISA determination. The experiment was set up with 3 replicates.

[0411] The results are shown in Table 5 below. 2',3'-cGAMP was used as a positive control, and the test results were expressed as the activity percentage relative to 20 μM concentration of 2',3'-cGAMP.

[0412] Table 5 Effect of the compounds of the present invention on IFNβ-induced secretion in THP1 cells

[0413]

[0414]

[0415] As can be seen from Table 5, the representative compounds of the present invention have good activity in inducing THP1 cells to secrete IFNβ, which can provide a basis for preparing drugs for preventing and / or treating STING-related diseases, or for preparing anti-tumor drugs in combination with immune checkpoint inhibitors. As described above, although the present invention has been represented and described with reference to specific preferred embodiments, it shall not be interpreted as a limitation on the present invention itself. Various changes may be made to it in form and detail without departing from the spirit and scope of the present invention as defined in the appended claims.

Claims

1. A dimeric compound having a benzo[b]selenophene structure, characterized in that: Includes the following compounds:

2. A pharmaceutical composition, characterized in that: The invention comprises the compound according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.

3. Use of the compound according to claim 1 in the preparation of drugs for activating the cGAS-STING pathway.

4. Use of the compound according to claim 1 in the preparation of a drug for preventing and / or treating STING-related diseases.

Citation Information

Patent Citations

  • Benzo [b] selenophene STING regulating agent as well as preparation method and application thereof

    CN113429387A

  • Heterocyclic amides useful as protein modulators

    WO2017175147A1

  • Agonists of stimulator of interferon genes sting

    WO2019165032A1

  • Benzothiophenes and related compounds as sting agonists

    CN111971277A